0001144204-17-057993.txt : 20171113 0001144204-17-057993.hdr.sgml : 20171110 20171113090132 ACCESSION NUMBER: 0001144204-17-057993 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 51 CONFORMED PERIOD OF REPORT: 20170930 FILED AS OF DATE: 20171113 DATE AS OF CHANGE: 20171113 FILER: COMPANY DATA: COMPANY CONFORMED NAME: REPROS THERAPEUTICS INC. CENTRAL INDEX KEY: 0000897075 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 760233274 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-15281 FILM NUMBER: 171193445 BUSINESS ADDRESS: STREET 1: 2408 TIMBERLOCH PL STREET 2: SUITE B-7 CITY: WOODLANDS STATE: TX ZIP: 77380 BUSINESS PHONE: 2817193400 MAIL ADDRESS: STREET 1: 2408 TIMBERLOCH PLACE B-7 CITY: THE WOODLANDS STATE: TX ZIP: 77380 FORMER COMPANY: FORMER CONFORMED NAME: REPROS THERAPEUTICS INC DATE OF NAME CHANGE: 20060503 FORMER COMPANY: FORMER CONFORMED NAME: ZONAGEN INC DATE OF NAME CHANGE: 19930208 10-Q 1 tv478357_10q.htm FORM 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2017

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ____________ to ____________

Commission file number: 001-15281

REPROS THERAPEUTICS INC.

(Exact Name of Registrant as Specified in its Charter)

Delaware

(State or other jurisdiction of
incorporation or
organization)

2408 Timberloch Place, Suite B-7

The Woodlands, Texas 77380

(Address of principal executive offices
and zip code)

(281) 719-3400

(Registrant's telephone number,
including area code)

76-0233274

(IRS Employer
Identification No.)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company or emerging growth company. See definition of "accelerated filer", "large accelerated filer", "smaller reporting company" and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer ¨

Accelerated filer ¨

Non-accelerated filer ¨

Smaller reporting company x

Emerging Growth Company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ¨.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

As of November 7, 2017, there were outstanding 39,555,133 shares of Common Stock, par value $.001 per share, of the Registrant.

REPROS THERAPEUTICS INC.

For the Quarter Ended September 30, 2017

INDEX

	Page
FACTORS AFFECTING FORWARD-LOOKING STATEMENTS	3

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements (unaudited)	4

Unaudited Condensed Consolidated Balance Sheets as of September 30, 2017 and December 31, 2016	5
Unaudited Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2017 and 2016	6
Unaudited Condensed Consolidated Statements of Stockholders' Equity for the nine months ended September 30, 2017 and 2016	7
Unaudited Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2017 and 2016	8
Notes to Unaudited Condensed Consolidated Financial Statements	9
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations	18
Item 3. Quantitative and Qualitative Disclosures About Market Risk	33
Item 4. Controls and Procedures	33

PART II. OTHER INFORMATION
Item 1. Legal Proceedings	34
Item 1A. Risk Factors	34
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	35
Item 3. Defaults Upon Senior Securities	35
Item 4. Mine Safety Disclosures	35
Item 5. Other Information	35
Item 6. Exhibits	35

SIGNATURES	37

FACTORS AFFECTING FORWARD-LOOKING STATEMENTS

This quarterly report on Form 10-Q includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words "may," "anticipate," "believe," "expect," "estimate," "project," "suggest," "intend" and similar expressions are intended to identify forward-looking statements. Such statements are subject to certain risks, uncertainties and assumptions. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, expected, estimated, projected, suggested or intended. These risks and uncertainties include risks associated with the success of the clinical trials for Proellex®; the progress of the Company’s enclomiphene product candidate; uncertainty related to the Company's ability to obtain approval of the Company's products by the Food and Drug Administration and regulatory bodies in other jurisdictions, including the European Medicines Agency; uncertainty relating to the Company's patent portfolio; and other risks and uncertainties described in the Company's filings with the Securities and Exchange Commission. For additional discussion of such risks, uncertainties and assumptions, see "Part I. Financial Information - Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations - Liquidity and Capital Resources" included elsewhere in this quarterly report on Form 10-Q and “Item 1A. Risk Factors” to Part I of Form 10-K for the fiscal year ended December 31, 2016.

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

The following unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments (which include only normal recurring adjustments) considered necessary for a fair statement of the interim periods presented have been included. The year-end balance sheet data was derived from audited financial statements, but does not include all the disclosures required by accounting principles generally accepted in the United States of America. Operating results for the three and nine month periods ended September 30, 2017 are not necessarily indicative of the results that may be expected for the year ending December 31, 2017. For further information, refer to the financial statements and footnotes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2016.

REPROS THERAPEUTICS INC. AND SUBSIDIARY

CONDENSED CONSOLIDATED BALANCE SHEETS

(unaudited and in thousands except share and per share amounts)

	September 30, 2017			December 31, 2016

ASSETS

Current assets
Cash and cash equivalents	$	1,813		$	8,688
Restricted cash		916			-
Prepaid expenses and other current assets		135			66
Total current assets		2,864			8,754
Fixed assets, net		-			3
Non-current restricted cash		919			-
Total assets	$	3,783		$	8,757

LIABILITIES AND STOCKHOLDERS’ EQUITY

Current liabilities
Accounts payable	$	1,246		$	1,880
Accrued expenses		1,192			779
Total current liabilities		2,438			2,659
Long-term liabilities
Accrued severance		916			-
Warrant liability		1,716			-
Total liabilities		5,070			2,659

Commitment & Contingencies (note 8)

Stockholders’ Equity
Undesignated Preferred Stock, $.001 par value, 5,000,000 shares authorized, none issued and outstanding		-			-
Common Stock, $.001 par value, 75,000,000 shares authorized, 39,602,157 and 25,938,602 shares issued, respectively; 39,489,807 and 25,826,252 shares outstanding, respectively, as of September 30, 2017 and December 31, 2016		40			26
Additional paid-in capital		329,305			326,981
Cost of treasury stock, 112,350 shares		(1,380	)		(1,380	)
Accumulated deficit		(329,252	)		(319,529	)
Total stockholders’ equity		(1,287	)		6,098
Total liabilities and stockholders’ equity	$	3,783		$	8,757

The accompanying notes are an integral part of these condensed consolidated financial statements.

REPROS THERAPEUTICS INC. AND SUBSIDIARY

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(unaudited and in thousands except per share amounts)

	Three Months Ended September 30,						Nine Months Ended September 30,
	2017			2016			2017			2016

Revenues and other income
Interest income	$	9		$	10		$	23		$	41
Change in fair value of warrant liability		295			-			135			-
Total revenues and other income		304			10			158		$	41
Expenses
Research and development		979			3,182			4,192			10,191
General and administrative		940			997			5,689			3,144
Total expenses		1,919			4,179			9,881			13,335
Net loss	$	(1,615	)	$	(4,169	)	$	(9,723	)	$	(13,294	)

Loss per share – basic and diluted	$	(0.04	)	$	(0. 17	)	$	(0.32	)	$	(0.55	)

Shares used in loss per share calculation:
Basic		37,598			24,495			30,797			24,372
Diluted		37,598			24,495			30,797			24,372

The accompanying notes are an integral part of these condensed consolidated financial statements.

REPROS THERAPEUTICS INC. AND SUBSIDIARY

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(unaudited and in thousands except share and per share amounts)

	Common Stock				Additional			Treasury Stock								Total
	Shares		Amount		Paid-in Capital			Shares		Amount			Accumulated Deficit			Stockholders’ Equity
Balance at December 31, 2016		25,938,602	$	26	$	326,981			112,350	$	(1,380	)	$	(319,529	)	$	6,098
Stock based compensation		-		-		680			-		-			-			680
Issuance of 849,157 shares of common stock pursuant to the Equity Distribution Agreement at a weighted average price of $1.20, net of offering costs of $32		849,157		1		1,020			-		-			-			1,021
Issuance of 2,744,125 shares of common stock at $0.60 per share, Series A and Series B warrants, and pre-funded Series C warrants at $0.60 per share in the May Public Offering, net of offering costs of $508		2,744,125		3		(1,213	)		-		-			-			(1,210	)
Exercise of 2,245,875 Series C Warrants to purchase common stock for cash at $0.001 per share		2,245,875		2		1,277			-		-			-			1,279
Net Number Cashless Exercise of 2,397,834 Series B Warrants to purchase common stock (share settlement of Warrant liability)		7,719,958		8		560			-		-			-			568
Issuance of 60,000 shares of restricted common stock		60,000		-		-			-		-			-			-
Issuance of 44,440 shares of common stock for vested RSUs		44,440		-		-			-		-			-			-
Net loss		-		-		-			-		-			(9,723	)		(9,723	)
Balance at September 30, 2017		39,602,157	$	40	$	329,305			112,350	$	(1,380	)	$	(329,252	)	$	(1,287	)

Balance at December 31, 2015		24,430,461	$	24	$	322,179			112,350	$	(1,380	)	$	(302,256	)	$	18,567
Stock based compensation		-		-		1,491			-		-			-			1,491
Exercise of 1,333 Series A warrants to purchase common stock for cash at $0.01 per share		1,333		-		-			-		-			-			-
Issuance of 807,340 shares of common stock at a weighted average price of $2.15, net of offering costs of $1450		807,340		1		1,593			-		-			-			1,594
Net loss		-		-		-			-		-			(13,294	)		(13,294	)
Balance at September 30, 2016		25,239,134	$	25	$	325,263			112,350	$	(1,380	)	$	(315,550	)	$	8,358

The accompanying notes are an integral part of these condensed consolidated financial statements.

REPROS THERAPEUTICS INC. AND SUBSIDIARY

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(unaudited and in thousands)

	Nine Months Ended September 30,
	2017			2016

Cash Flows from Operating Activities
Net loss	$	(9,723	)	$	(13,294	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation		3			4
Noncash stock-based compensation		680			1,491
Change in fair value of warrant liability		(135	)		-
Increase in prepaid expenses and other current assets		(70	)		(74	)
Increase (decrease) in accounts payable and accrued expenses		696			(609	)
Net cash used in operating activities		(8,549	)	$	(12,482	)

Cash Flows from Investing Activities
Capital expenditures		-			-
Net cash used in investing activities		-			-

Cash Flows from Financing Activities
Issuance of common stock and warrants, net of offering costs		3,507			1,594
Proceeds from exercise of stock warrants		2			-
Net cash provided by financing activities		3,509			1,594
Net decrease in cash, cash equivalents and restricted cash		(5,040	)		(10,888	)
Cash, cash equivalents and restricted cash at beginning of period		8,688			21,393
Cash, cash equivalents and restricted cash at end of period	$	3,648		$	10,505

Noncash transactions:
Settlement of warrant liability due to cashless warrant exercises	$	(568	)		-

The accompanying notes are an integral part of these condensed consolidated financial statements.

REPROS THERAPEUTICS INC. AND SUBSIDIARY

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2017

(Unaudited)

NOTE 1 — Organization, Operations, Liquidity and Recent Developments

Repros Therapeutics Inc. (the “Company,” “RPRX,” “Repros,” or “we,” “us” or “our”) was organized on August 20, 1987. We are a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders.

We are developing Proellex®, an orally administered selective blocker of the progesterone receptor in women, for the treatment of uterine fibroids and endometriosis. Uterine fibroids and endometriosis affect millions of women of reproductive age. Proellex® has shown statistically significant results in previous Phase 2 studies for uterine fibroids and endometriosis. We completed a low dose escalating study as permitted by the Food and Drug Administration (“FDA”) in late 2011, to determine both signals of efficacy and safety for low oral doses of the drug. There was no evidence of elevations of liver enzymes over baseline, suggesting these lower doses avoid the type of adverse events seen at much higher doses in earlier studies. On March 17, 2014, we announced that the FDA indicated that we may proceed to conduct Phase 1 and Phase 2 studies of low dose oral Proellex® for uterine fibroids and endometriosis while remaining on partial clinical hold. This guidance indicated that the highest allowed dose will be 12 mg daily. On December 29, 2014, we announced that we have initiated a Phase 2B study for low dose oral Proellex® in the treatment of uterine fibroids. This study was fully enrolled in January 2016 and on November 14, 2016, we announced positive clinical data from this study after two 18-week courses of treatment as compared to placebo. On April 10, 2017, the Company announced that it had a meeting with the FDA to discuss the progress and next steps in the development of Proellex® for the treatment of uterine fibroids. Shortly before the meeting, the Company was notified that the meeting would be a type C/Guidance meeting, rather than a type B/End of phase 2 meeting as previously anticipated. At the meeting, the FDA confirmed that Proellex® will continue on the current partial clinical hold while they consult with liver experts within the FDA regarding previously disclosed effects on the liver. On July 17, 2017, the Company announced that it received preliminary feedback from the FDA on the oral Proellex® clinical development program. The Proellex^® program will remain on partial clinical hold, and based upon the FDA’s review of all the existing liver function safety data, the FDA has indicated that the Company will be required to compile a large pre-approval safety data base to support future development.

The Company has an active Investigational New Drug Application (“IND”) for the vaginal delivery of Proellex® for the treatment of uterine fibroids. Since the clinical hold relates only to oral delivery of Proellex®, this IND has no clinical hold issues. In the first quarter of 2012, we initiated a Phase 2 vaginal administration study for the treatment of uterine fibroids and subsequently reported the final study results in January 2013. We held an end of Phase 2 meeting with the FDA in May 2013, to discuss a Phase 3 study design for vaginally delivered Proellex as a treatment for uterine fibroids. The FDA recommended that a Phase 2B study should be conducted prior to commencing a Phase 3 program. On December 29, 2014, we announced that we have initiated a Phase 2B study for vaginally delivered Proellex® in the treatment of uterine fibroids. This study was fully enrolled in January 2016 and on November 14, 2016, we announced positive clinical data from this study after two 18-week courses of treatment as compared to placebo. In light of the FDA guidance on the oral Proellex® development program, the Company is assessing increasing its focus on the vaginal delivery of Proellex®.

We are also developing enclomiphene, a single isomer of clomiphene citrate which is an orally active proprietary small molecule compound. Enclomiphene is for the treatment of secondary hypogonadism in overweight men wishing to restore normal testicular function. Men with secondary hypogonadism exhibit low testosterone levels due to under stimulated testes but they are generally fertile. Enclomiphene is designed to treat the underlying mechanism, insufficient stimulation of the testes by the pituitary, which causes secondary hypogonadism. Secondary hypogonadism due to being overweight or obese is the single greatest cause of hypogonadism in general.

On February 2, 2015, we announced that we electronically submitted our New Drug Applications (“NDA”) to the FDA for enclomiphene. The FDA accepted the NDA for review on April 1, 2015 and later assigned a Prescription Drug User Fee (“PDUFA”) goal date of November 30, 2015. In addition, the Division of Bone, Reproductive and Urologic Products (the “Division”) of the FDA scheduled an advisory committee meeting to review the NDA for November 3, 2015. However, the Division subsequently cancelled the scheduled advisory committee meeting due to questions that arose late in the review regarding the bioanalytical method validation that could affect interpretability of certain pivotal study data. On December 1, 2015, we announced that we had received a Complete Response Letter (“CRL”) from the FDA. A CRL informs companies that an NDA cannot be approved in its present form. In the CRL, the FDA stated that, based on recent scientific developments, the design of the enclomiphene Phase 3 studies is no longer adequate to demonstrate clinical benefit and recommended that Repros conduct an additional Phase 3 study or studies to support approval in the target population. The FDA also noted concerns regarding study entry criteria, titration and bioanalytical method validation in the Phase 3 program.

Subsequently, on February 4, 2016, the Company attended a meeting with the FDA reviewers and senior leaders to discuss resolution of issues identified during the NDA review. The meeting covered a broad range of topics surrounding the NDA data as well as emerging agency and expert thinking regarding the treatment of hypogonadism. The Company believes based on the meeting that the FDA is not closed to considering secondary hypogonadism as an indication. Additionally, in January 2016, the Company initiated a Phase 2 double-blind, placebo controlled, proof of concept study, ZA-205, in obese secondary hypogonadal men to assess the impact of enclomiphene on metabolic parameters and quality of life under a diet and exercise regimen. This study was fully enrolled in February 2016 and on August 15, 2016, we reported six month interim results from this study.

Additionally, on September 12, 2016, we reported that we successfully submitted a European centralized marketing authorization application (“MAA”) for enclomiphene for the treatment of secondary hypogonadism. This MAA was subsequently accepted by the European Medicines Agency (“EMA”) which, as previously reported, has assigned the United Kingdom as the primary rapporteur and France as the co-rapporteur for the application review. As part of the ongoing review process, the Company has filed responses to the EMAs questions in the third quarter of 2017.

On December 6, 2016, the Company participated in the industry presentation at the Bone, Reproductive and Urologic Drugs’ Advisory Committee meeting. The advisory panel provided the FDA with advice regarding a clinical and regulatory path to approval for products, such as enclomiphene, in subjects with obesity-related hypogonadism who wish to maintain spermatogenesis. The panel voted 16 to 5 that the achievement of testosterone improvement while maintaining evidence of spermatogenesis was not sufficient, in and of itself, to provide evidence of clinical benefit. At the meeting, numerous panel members suggested that an additional endpoint related to symptoms should be assessed.

Liquidity

On August 9, 2016, we entered into an Equity Distribution Agreement (the “Equity Distribution Agreement”) with Ladenburg Thalmann & Co. Inc. (“Ladenburg”), pursuant to which we had the ability to issue and sell from time to time through Ladenburg, as sales agent and/or principal, shares of our common stock having an aggregate offering price of up to $10 million (the “ATM Shares”). Ladenburg had no obligation to sell on our behalf any specific number or dollar amount of the ATM Shares, but Ladenburg, upon acceptance of written instructions from us, agreed to use its commercially reasonable efforts consistent with its customary trading and sales practices, to sell the ATM Shares up to the amount specified, and otherwise in accordance with the terms of a placement notice delivered to Ladenburg. Ladenburg was entitled to receive a commission of 3% of the gross sales price of all ATM Shares sold through it under the Equity Distribution Agreement. Effective May 9, 2017, the Company terminated the Sales Agreement and the related ATM Program. During the nine month period ended September 30, 2017, we sold 849,157 ATM Shares at a weighted average share price of $1.20 for proceeds of approximately $1,021,000, net of expenses including approximately $32,000 in commissions to Ladenburg.

On May 23, 2017, the Company sold 2,744,125 shares of common stock and pre-funded Series C Warrants to purchase up to 2,245,875 shares of common stock in an underwritten public offering to certain investors (the “May Public Offering”). Each share of common stock was sold at a price of $0.60 and each Series C Warrant was issued with an exercise price of $0.60 per share of common stock, $0.60 of which was pre-funded at closing and $0.001 was payable upon exercise. This May Public Offering also included the issuance of Series A Warrants to purchase 3,742,500 shares of our common stock at an initial exercise price of $0.84 per share and Series B Warrants to purchase 2,495,000 shares of our common stock at an initial exercise price of $0.92 per share. Each share of common stock and each pre-funded Series C Warrant to purchase a share of common stock were sold together with a Series A Warrant to purchase 0.75 share of common stock and a Series B Warrant to purchase 0.50 share of common stock. The net proceeds to the Company from the sale of common stock and warrants, after deducting underwriting discounts and commissions and other offering expenses, were approximately $2.5 million. For further discussion of the May Public Offering, see Note 6 to the financial statements included herein.

As of September 30, 2017, we had accumulated losses of $329.3 million, approximately $1.8 million in cash and cash equivalents, and accounts payable and accrued expenses of approximately $3.4 million, in the aggregate. Included in our accrued expenses is $1.8 million related to the accrued severance payments due Mr. Podolski upon his termination, which are anticipated to be paid in the first quarter of 2018 and 2019 with our restricted cash of $1.8 million. We anticipate that our current liquidity will be sufficient to continue the development of our product candidates (to the extent we deem appropriate) and meet our obligations as they become due through the end of 2017. We continue to explore potential additional financing alternatives, including corporate partnering opportunities, that would provide sufficient funds to enable us to continue to develop our two product candidates through FDA approval; however, there can be no assurance that we will be successful in raising any such additional funds on a timely basis or at all. The foregoing matters raise substantial doubt about our ability to continue as a going concern.

Nasdaq Listing

On November 8, 2017, we received written notification from the Listing Qualifications Staff (the “Staff”) of The NASDAQ Stock Market LLC (“Nasdaq”) indicating that, based upon our continued non-compliance with the minimum stockholders’ equity requirement for continued listing on The NASDAQ Capital Market, as set forth in NASDAQ Marketplace Rule 5550(b)(2) (the “Stockholders’ Equity Rule”), the Staff had determined to delist our common stock from Nasdaq (the “Staff Determination”) unless we timely request a hearing before the Nasdaq Hearings Panel (the “Panel”). We will have until November 15, 2017 to request a hearing.

We intend to timely request a hearing before the Panel, which request will stay any suspension or delisting action by Nasdaq at least until the hearing process concludes and any extension granted by the Panel expires. At the hearing, we plan to present our plan to evidence compliance with the Stockholders’ Equity Rule, and request an extension of time within which to do so.

The November 8, 2017 notice has no immediate effect on the listing of our common stock and the common stock will continue to trade on the NASDAQ Capital Market under the symbol “RPRX” at least until the hearing process concludes and any extension granted by the Panel expires.

Basis of Presentation

These financial statements are unaudited; however, in the opinion of management, these statements reflect all adjustments necessary for a fair statement of the results for the periods reported. All such adjustments are of a normal recurring nature unless disclosed otherwise. These financial statements, including notes, have been prepared in accordance with the applicable rules of the SEC and do not include all of the information and disclosures required by U.S. GAAP for complete financial statements.

These interim financial statements should be read in conjunction with the financial statements and notes thereto included in our 2016 Annual Report on Form 10-K. The results of operations for the three and nine month periods ended September 30, 2017 are not necessarily indicative of the results to be expected for the full year.

Changes in Accounting Policies

In November 2016, the FASB issued ASU No. 2016-18, “Statement of Cash Flows (Topic 230): Restricted Cash”. The new standard requires restricted cash to be included with cash and cash equivalents when reconciling the beginning and ending amounts on the statement of cash flows, and requires additional disclosures in the notes to the financial statements. ASU 2016-18 is effective for fiscal years beginning after December 15, 2017 and interim periods within those fiscal years and early adoption is permitted. The Company adopted this standard during the quarter ended March 31, 2017. See Note 2 to the financial statements included herein.

In March 2016, the FASB issued ASU 2016-09, Compensation—Stock Compensation (ASC Topic 718): Improvements to Employee Share-Based Payment Accounting. The new standard simplifies the accounting for stock-based compensation, including amendments on how both taxes related to stock-based compensation and cash payments made to taxing authorities are recorded. ASU 2016-09 is effective for annual reporting periods beginning on or after December 15, 2016, and interim periods within those annual periods and early application is permitted, with any adjustments reflected as of the beginning of the fiscal year of adoption. The Company adopted ASU 2016-09 effective January 1, 2017. The adoption of this standard did not have a material effect on the Company’s financial statements.

In November 2015, the FASB issued ASU No. 2015-17, “Balance Sheet Classification of Deferred Taxes” (“ASU 2015-17”), which requires entities to present deferred tax assets and deferred tax liabilities as noncurrent in a classified balance sheet. The ASU simplifies the current guidance in ASC Topic 740, Income Taxes, which requires entities to separately present deferred tax assets and liabilities as current and noncurrent in a classified balance sheet. ASU 2015-17 is effective for fiscal years beginning after December 15, 2016, and interim periods within those annual periods. The Company adopted ASU 2015-07 effective January 1, 2017. The adoption of this standard did not have a material effect on the Company’s financial statements.

New Accounting Pronouncements Not Yet Adopted

In July 2017, the FASB issued ASU No. 2017-11, “(Part I) Accounting or Certain Financial Instruments with Down Round Features” (“ASU 2017-11”), which changes the classification analysis of certain equity-linked financial instruments with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature will no longer preclude equity classification when assessing whether the instrument is indexed to an entity’s own stock. ASU 2017-11 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. The Company is currently evaluating the impact of this standard on its consolidated financial statements.

In February 2016, FASB issued ASU 2016-02, Leases (ASC Topic 842), which supersedes ASC Topic 840, Leases. The new standard is intended to increase transparency and comparability of organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. The new guidance is effective for financial statements issued for annual reporting periods beginning after December 15, 2018, and early application is permitted. The Company is currently evaluating the impact of this standard on its consolidated financial statements.

In May 2014, the FASB issued Accounting Standards Update 2014-09, “Revenue from Contracts with Customers” (“ASU 2014-09”). ASU 2014-09 is a comprehensive new revenue recognition model requiring a company to recognize revenue to depict the transfer of goods or services to a customer at an amount reflecting the consideration it expects to receive in exchange for those goods or services. In adopting ASU 2014-09, companies may use either a full retrospective or a modified retrospective approach. Additionally, this guidance requires improved disclosures regarding the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. On July 9, 2015, the FASB voted to delay the effective date of this standard by one year. This deferral resulted in ASU 2014-09 being effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017, with early adoption being permitted for annual periods beginning after December 15, 2016. Entities have the option of using either a full retrospective or a modified retrospective approach to adopt the guidance. The Company is currently assessing the effects this guidance may have on its consolidated financial statements, as well as the method of transition that the Company will use in adopting the new standard.

NOTE 2 — Cash, Cash Equivalents and Restricted Cash

As of September 30, 2017, the Company maintained $1.8 million as restricted cash. The funds are being held in accordance with the Release Agreement entered into with Mr. Podolski on February 1, 2017.

The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the balance sheets that sum to the total of the same such amounts shown in the statements of cash flows (in thousands):

	September 30, 2017		September 30, 2016
Cash and cash equivalents	$	1,813	$	10,505
Restricted cash, current		916		—
Restricted cash, noncurrent		919		—
Total	$	3,648	$	10,505

NOTE 3 — Accrued Expenses

Accrued expenses consist of the following (in thousands):

	September 30, 2017		December 31, 2016
Current accrued expenses:
Personnel related costs	$	1,045	$	512
Research and development costs		27		174
Other		120		93
Total current accrued expenses	$	1,192	$	779

Long-term accrued expenses:
Accrued severance	$	916	$	—
Total long-term accrued expenses	$	916	$	—

NOTE 4 — Loss Per Share

Basic loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted loss per share is computed using the average shares outstanding for the period and applying the treasury stock method to potentially dilutive outstanding options, restricted stock units and warrants. In all applicable periods, all potential common stock equivalents were anti-dilutive and, accordingly, were not included in the computation of diluted loss per share.

The following table presents information necessary to calculate loss per share for the three and nine month periods ended September 30, 2017 and 2016 (in thousands, except per share amounts):

	Three Months Ended September 30,						Nine Months Ended September 30,
	2017			2016			2017			2016
Net loss	$	(1,615	)	$	(4,169	)	$	(9,723	)	$	(13,294	)
Average common shares outstanding		37,598			24,495			30,797			24,372
Basic and diluted loss per share	$	(0.04	)	$	(0.17	)	$	(0.32	)	$	(0.55	)

Potential common stock of 2,698,082 common shares underlying stock options and restricted stock units and common shares underlying 3,839,666 stock purchase warrants for the period ended September 30, 2017, were excluded from the above calculation of diluted loss per share because they were anti-dilutive. Potential common stock of 2,792,357 common shares underlying stock options for the period ended September 30, 2016, were also excluded from the above calculation of diluted loss per share because they were anti-dilutive.

NOTE 5 – Stock-Based Compensation

On February 1, 2017, the Board of Directors (the “Board”) granted Larry Dillaha, the Company’s then interim President and Chief Executive Officer a grant of 50,000 stock options to vest upon the successful completion of certain milestones. Additionally, the Board awarded to Katherine Anderson, the Company’s Chief Financial Officer, 10,000 restricted shares of common stock per month on the first day of each month beginning February 1, 2017 and ending on July 1, 2017, to vest on the last day of the month of grant. On February 13, 2017, the Board awarded Michael Wyllie, a non-employee director of the Company, and Larry Dillaha, a grant of 50,000 stock options each. Both option awards will vest upon the successful completion of certain milestones. On February 13, 2017, the Board awarded each board member a grant of 40,000 restricted stock units, to settle in shares of the Company’s common stock and to vest in equal monthly installments over the three years following the date of grant. On September 15, 2017, the Board awarded each board member a grant of 5,000 stock options each to vest in equal monthly installments over the next twelve months following the date of grant. Additionally, during the nine month period ended September 30, 2017, 424,835 stock options either expired or were forfeited.

NOTE 6 — Stockholders’ Equity

Offerings

No ATM Shares were sold during the three month period ended September 30, 2017 due to the termination of the ATM program in May 2017. The table below summarizes our ATM Shares sold during the nine month period ended September 30, 2017 (in thousands, except share and per share amounts):

	Nine Months Ended September 30, 2017

ATM Shares sold		849,157
Weighted average share price	$	1.20
Net proceeds, net of offering costs	$	1,021
Offering commissions to Ladenburg	$	32

The Series A warrants are exercisable, subject to certain limitations, upon issuance and expire five years from issuance and the Series B and Series C warrants are exercisable, subject to certain limitations, upon issuance and expire two years from issuance. The Series A and Series B warrants contain anti-dilution provisions that reduce the exercise price of the warrants if certain dilutive issuances occur, subject to a floor of $0.17 per share. Each of the warrants contain a cashless exercise provision in the event there is no effective registration statement covering the shares to be issued upon exercise of the warrants and a net cash settlement feature at the option of the warrant holder in certain limited circumstances in which the Company fails to timely deliver registered common shares upon a warrant exercise. Additionally, beginning 30 days after the issuance date, a Series B warrant holder is permitted to effect a cashless exercise and receive a net number of shares equal to the product of (i) 200% of the applicable warrant exercise percentage of the initial warrant amount and (ii) the quotient obtained by dividing (a) the difference obtained by subtracting (x) the market price, from (y) the initial exercise price of the Series B Warrants by (b) the market price (the “Net Number Cashless Exercise”).

Due to the net cash settlement feature at the option of the warrant holder discussed above, the Series A and Series B warrants are classified as liabilities under the caption “Warrant liability” in the accompanying balance sheets and recorded at estimated fair value at issuance with any subsequent change in fair value of the outstanding warrants since issuance reflected in “Change in fair value of warrant liability” in the accompanying statements of operations. Additionally, any share settlement of the warrant liability upon a warrant exercise is reflected as a noncash settlement of the pro-rata share of the warrant liability and issuance of common stock. See Note 7 to the financial statements included herein for discussion regarding the fair value of the warrants.

The following table reflects the warrant activity of the Company for the nine month period ended September 30, 2017:

	Series A		Series B			Series C			Shares of Common Stock
	Warrants		Warrants			Warrants			Issued
Balance, December 31, 2016		—		—			—
Issuance of warrants		3,742,500		2,495,000			2,245,875
Series C Warrants exercised to purchase common stock for cash at $0.001 per share		—		—			(2,245,875	)		2,245,875
Net Number Cashless Exercise of Series B Warrants		—		(2,397,834	)		—			7,719,958
Balance, September 30, 2017		3,742,500		97,166			—

Through November 13, 2017, an additional 13,833 Series B Warrants were exercised under the cashless alternative provision and as a result the Company has issued 59,771 shares of common stock.

On July 24, 2017, the Company filed a shelf registration statement on Form S-3 (File No. 333-219428, the “July 2017 Registration Statement”) to permit the continued exercise of the Series A Warrants and Series B Warrants following the expiration, on that date, of the Company’s prior Registration Statement on Form S-3, as amended (File No. 333-197253). The July 2017 Registration Statement was declared effective by the SEC on August 4, 2017. Between the expiration of the prior registration statement and the effectiveness of the July 2017 Registration Statement, exercises of the Series A Warrants and Series B Warrants continued to be permitted under the prior registration statement pursuant to Rule 415(a)(5) under the Securities Act of 1933, as amended.

NOTE 7 — Fair Value Measurements

The FASB has established a framework for measuring fair value in generally accepted accounting principles. That framework provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurements) and the lowest priority to unobservable inputs (level 3 measurements). The three levels of the fair value hierarchy are described as follows:

Level 1. Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets.

Level 2. Inputs to the valuation methodology include:

	·	Quoted prices for similar assets or liabilities in active markets

		Quoted prices for identical or similar assets or liabilities in inactive markets

	·	Inputs other than quoted prices that are observable for the asset or liability

	·	Inputs that are derived principally from or corroborated by observable market data by correlation or other means

If the asset or liability has a specified (contractual) term, the level 2 input must be observable for substantially the full term of the asset or liability.

Level 3. Inputs to the valuation methodology are unobservable and significant to the fair value measurement.

The asset or liability’s fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques used need to maximize the use of observable inputs and minimize the use of unobservable inputs.

The table below presents our assets and liabilities that are measured at fair value on a recurring basis at September 30, 2017 and are categorized using the fair value hierarchy (in thousands):

	Total			Level 1		Level 2			Level 3
Cash and cash equivalents	$	1,813		$	1,813	$	—		$	—
Restricted cash	$	1,835		$	1,835	$	—		$	—
Warrant liability	$	(1,716	)	$	—	$	(1,716	)	$	—

The table below presents our assets and liabilities that are measured at fair value on a recurring basis at December 31, 2016 and are categorized using the fair value hierarchy (in thousands):

		Total				Level 1				Level 2				Level 3
Cash and cash equivalents		$	8,688			$	8,688			$	—			$	—

All cash and cash equivalents and restricted cash as of September 30, 2017 and December 31, 2016 were held in accounts backed by U.S. government securities.

On May 23, 2017, as a result of the May Public Offering (described in Note 6 to the financial statements included herein), the Company issued Series A, Series B and Series C warrants that include a net cash settlement feature at the option of the warrant holder in certain limited circumstances in which the Company fails to timely deliver registered common shares upon a warrant exercise. All Series C warrants were exercised in June 2017. The Series A and Series B warrants are classified as liabilities under the caption “Warrant liability” in the accompanying balance sheets and recorded at estimated fair value at issuance with any subsequent change in fair value of the outstanding warrants since issuance reflected in “Change in fair value of warrant liability” in the accompanying statements of operations. The fair value of the Series A and Series B warrant liability at the issue date was $2,419,000 after giving effect to anti-dilution adjustments under the assumption that the anti-dilution mechanism contained in the Series A and Series B warrants was in effect. The following summarizes the change in the Warrant liability for the nine months ended September 30, 2017 (in thousands):

	Series A Warrants			Series B Warrants			Total
Warrant liability at date of issue	$	(1,831	)	$	(588	)	$	(2,419	)
Share settlement due to warrant exercises		-			568			568
Change in fair value		134			1			135
Warrant liability at September 30, 2017	$	(1,697	)	$	(19	)	$	(1,716	)

The Company will continue to adjust the Warrant liability for changes in fair value of the outstanding warrants until the earlier of the exercise of the warrants, modification of the warrants, or expiration of the warrants.

The fair value of the Company’s warrant liability recorded in the Company’s financial statements was determined using the Monte Carlo simulation valuation method with the quoted market price of the Company’s common stock, expected volatility of the Company’s stock, no dividend yield, an expected life based on the remaining contractual term of the outstanding warrants and a risk-free interest rate based on USD overnight indexed swaps with a maturity equivalent to the warrants’ expected life.

The Company calculated the estimated fair value of the Series A and Series B warrants on the issuance date and at September 30, 2017 using the following weighted average assumptions:

	Issue Date
	(May 23, 2017)			September 30, 2017
Risk-free interest rate		1.46	%		1.99	%
Contractual term		3.3 years			4.6 years
Expected volatility		85.8	%		117.3	%

NOTE 8 — Commitments and Contingencies

None.

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

The following discussion contains forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act") and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act") that involve risk and uncertainties. Any statements contained in this quarterly report that are not statements of historical fact may be forward-looking statements. When we use the words "may," "anticipates," "believes," "plans," "expects" and similar expressions, we are identifying forward-looking statements. Forward-looking statements involve risks and uncertainties which may cause our actual results, performance or achievements to be materially different from those expressed or implied by forward-looking statements. The following discussion of financial condition should be read in conjunction with the accompanying consolidated financial statements and related notes.

Repros Therapeutics Inc.

The Company was organized on August 20, 1987. We are a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders.

We are developing Proellex®, an orally administered selective blocker of the progesterone receptor in women, for the treatment of uterine fibroids and endometriosis. Uterine fibroids and endometriosis affect millions of women of reproductive age. Proellex® has shown statistically significant results in previous Phase 2 studies for uterine fibroids and endometriosis. We completed a low dose escalating study as permitted by the Food and Drug Administration (“FDA”) in late 2011, to determine both signals of efficacy and safety for low oral doses of the drug. There was no evidence of elevations of liver enzymes over baseline, suggesting these lower doses avoid the type of adverse events seen at much higher doses in earlier studies. On March 17, 2014, we announced that the FDA indicated that we may proceed to conduct Phase 1 and Phase 2 studies of low dose oral Proellex® for uterine fibroids and endometriosis while remaining on partial clinical hold. This guidance indicated that the highest allowed dose will be 12 mg daily. On December 29, 2014, we announced that we have initiated a Phase 2B study for low dose oral Proellex® in the treatment of uterine fibroids. This study was fully enrolled in January 2016 and on November 14, 2016, we announced positive clinical data from this study after two 18-week courses of treatment as compared to placebo. On April 10, 2017, the Company announced they had a meeting with the FDA to discuss the progress and next steps in the development of Proellex® for the treatment of uterine fibroids. Shortly before the meeting, the Company was notified that the meeting would be a type C/Guidance meeting, rather than a type B/End of phase 2 meeting as previously anticipated. At the meeting, the FDA confirmed that Proellex® will continue on the current partial clinical hold while they consult with liver experts within the FDA regarding previously disclosed effects on the liver. On July 17, 2017, the Company announced that it received preliminary feedback from the FDA on the oral Proellex® clinical development program. The Proellex^® program will remain on partial clinical hold, and based upon the FDA’s review of all the existing liver function safety data, the FDA has indicated that the Company will be required to compile a large pre-approval safety data base to support future development.

In December 2011, we completed a Phase 2B study of enclomiphene in men with secondary hypogonadism, but naïve to testosterone treatment, at the recommendation of the FDA. Top line results of this study demonstrated that enclomiphene was generally well tolerated compared to placebo and that there were no drug related serious adverse events that led to discontinuation. We met with the FDA in May 2012 to discuss the design of pivotal Phase 3 efficacy studies for enclomiphene as well as the components of the overall drug development program required for a New Drug Application (“NDA”) submission and agreed on registration requirements for enclomiphene oral therapy for the treatment of secondary hypogonadism. In July 2012, we announced that we reached an agreement with the FDA for the design of the pivotal efficacy studies for enclomiphene for the treatment of secondary hypogonadism. The pivotal studies were conducted under a Special Protocol Assessment (“SPA”). We have completed both Phase 3 pivotal efficacy studies. On March 27, 2013, we announced that the top-line results from our first pivotal Phase 3 study, ZA-301, met both co-primary endpoints mandated by the FDA, and we announced on September 16, 2013, that we met both co-primary endpoints in the second pivotal study, ZA-302. Additionally, on September 16, 2013, we announced the results from ZA-300, a six-month safety study. This study identified no new safety issues. On October 22, 2013, we announced that we received guidance from the FDA instructing the Company to request a meeting to discuss the adequacy of studies ZA-301 and ZA-302. In addition to this guidance, the FDA further noted that they would allow us to run head-to-head studies against approved testosterone replacement products. These head-to-head studies, ZA-304 and ZA-305, were initiated in January 2014 and subsequently completed in September and August 2014, respectively. Both of these head-to-head studies achieved superiority for both co-primary endpoints and most secondary endpoints as compared to the approved testosterone replacement product. On October 21, 2014, we announced the results from ZA-303, a 52 week, single-blind, placebo-controlled Phase 3 study to evaluate the effects on bone mineral density. In this study, no new safety signals were identified, including no evidence of negative effects on bone mineral density. On February 2, 2015, we announced that we electronically submitted our NDA to the FDA for enclomiphene. The FDA accepted the NDA for review on April 1, 2015 and later assigned a Prescription Drug User Fee (“PDUFA”) goal date of November 30, 2015. In addition, the Division of Bone, Reproductive and Urologic Products (the “Division”) of the FDA scheduled an advisory committee meeting to review the NDA for November 3, 2015. However, the Division subsequently cancelled the scheduled advisory committee meeting due to questions that arose late in the review regarding the bioanalytical method validation that could affect interpretability of certain pivotal study data. On December 1, 2015, we announced that we had received a Complete Response Letter (“CRL”) from the FDA. A CRL informs companies that an NDA cannot be approved in its present form. In the CRL, the FDA stated that, based on recent scientific developments, the design of the enclomiphene Phase 3 studies is no longer adequate to demonstrate clinical benefit and recommended that Repros conduct an additional Phase 3 study or studies to support approval in the target population. The FDA also noted concerns regarding study entry criteria, titration and bioanalytical method validation in the Phase 3 program.

Liquidity

Nasdaq Listing

Proellex®

Product Overview

Proellex®, our product candidate for female reproductive health, is a new chemical entity that acts as a selective blocker of the progesterone receptor and is being developed for the treatment of symptoms associated with uterine fibroids and endometriosis. The National Uterine Fibroids Foundation estimates that 80% of all women in the U.S. have uterine fibroids, and one in four of these women have symptoms severe enough to require treatment. According to the Endometriosis Association, endometriosis affects 6.3 million women in the U.S. and Canada and millions more worldwide.

The current standards of care for uterine fibroids and endometriosis consist of surgery or short-term treatment with gonadotropin-releasing hormone (“GnRH”) agonists drugs, such as Lupron®. GnRH agonists induce a low estrogen, menopausal-like state and promote bone loss and are not recommended for use for more than six months without add-back hormonal therapy.

We have conducted numerous studies with Proellex® dosing approximately 900 women with the drug. All Proellex® studies completed to date exhibited strong efficacy signals, whether in uterine fibroids or endometriosis. In a 120 patient study of Proellex® as a treatment of uterine fibroids conducted in the United States (roughly 40 subjects per arm), both a 12.5 and 25 mg dose of Proellex® were compared to placebo. In this study each of the 12.5 and 25 mg doses achieved highly statistically significant results when compared to placebo when menstrual bleeding was assessed (p<0.0001). The two doses also achieved highly statistically significant improvement in quality of life measures using the Uterine Fibroid Symptom Quality of Life questionnaire developed and validated by Georgetown University and used in the development of device like treatments of uterine fibroids such as uterine artery embolization. There was no statistical difference in efficacy measures between the two doses. Importantly, in the Phase 2 U.S. trial, a significant percentage of women stopped menstruating (amenorrhea). Over 80% of women on both the 12.5 and 25 mg doses exhibited amenorrhea during the three month trial, whereas all women on placebo exhibited at least one menses. The key symptom of uterine fibroids is excessive menstrual bleeding. The induction of amenorrhea continues to be the primary endpoint in our uterine fibroids clinical studies.

Up until the summer of 2009, all side effects exhibited in the studies were considered manageable and the benefit of Proellex® far outweighed the risk. However, in Phase 3 efficacy and larger Phase 3 safety studies in diverse populations, a small number of subjects exhibited serious adverse effects associated with elevated liver enzymes. As a result of these findings, we elected to stop the trials and the FDA subsequently placed Proellex® on full clinical hold. All women that experienced elevated liver enzymes and returned for follow-up visits returned to baseline conditions with no overnight hospitalization necessary. An analysis of all the subjects that experienced such serious adverse effects showed that the effect only occurred in a small percentage of subjects that were exposed to the 50 mg dose of the drug for any period of time. Based on these findings, we petitioned the FDA to allow us to conduct a low dose study to demonstrate both safety and signals of efficacy in low oral doses of Proellex®, up to 12 mg administered daily. The FDA upgraded the full clinical hold to a partial hold to allow the low dose study to be conducted. In addition, we are exploring vaginal delivery as an alternative administrative route to bypass first-pass liver effects and reduce systemic exposure.

Low Dose Oral Study

Pursuant to the terms of the partial clinical hold currently in place as a result of the liver toxicity exhibited by Proellex®, the FDA allowed us to run a single study to test low oral doses of Proellex® for signals of safety and efficacy. The study tested five different doses of Proellex® (1, 3, 6, 9 and 12 mg), with 1 mg being the first dose tested. Each dose was then compared to placebo with weekly assessments of liver function during both the placebo and drug period. Subjects were dosed with the active drug for 10 weeks, which allowed for adequate time to determine the impact of a given dose on trends in liver function. Each dose was tested in up to 12 different subjects and assessment of pharmacokinetic parameters was obtained at the start of dosing and the end of the dosing period to determine overall and maximum drug exposure for a given dose. We also monitored changes in menstrual bleeding patterns and ovulation as well as changes in endometrial thickness. The FDA required that an independent Drug Safety Monitoring Board be established and that the informed consent clearly state the liver toxicity previously experienced with Proellex®. We have completed this study and have announced that there was no evidence of elevations of liver enzymes over baseline, suggesting these lower doses avoid the type of adverse events seen at much higher doses in earlier studies.

On July 16, 2012, we announced that we held a teleconference with the FDA to discuss the development of low dose oral Proellex® as a treatment for endometriosis. Subsequently, on October 8, 2012, we announced that the FDA has agreed to reclassify the full clinical hold to a partial clinical hold on low dose oral Proellex® to allow us to conduct a Phase 2 study in the treatment of endometriosis. We initiated this 60 subject, four month active dosing study in November 2012 and it was fully enrolled in January 2016. On September 7, 2016, we announced positive clinical data for the first course of treatment in this Phase 2 study.

On October 31, 2013, the Company held a meeting with the FDA to discuss the clinical development plan for low dose oral Proellex® in the treatment of uterine fibroids. During the meeting, the FDA provided guidance for endpoints it believed acceptable for the treatment of uterine fibroids in an efficacy study and instructed the Company to submit a request for lifting the full clinical hold. The Company has followed the FDA’s recommendations and submitted the study protocol and the request for the full hold lift. Additionally, on March 17, 2014, we announced that the FDA indicated that we may proceed to conduct Phase 1 and Phase 2 studies of low dose oral Proellex® for endometriosis and uterine fibroids while remaining on partial clinical hold. This guidance indicated that the highest allowed dose will be 12 mg daily. On December 29, 2014, we announced that we have initiated a Phase 2B study for low dose oral Proellex® in the treatment of uterine fibroids. This study was fully enrolled in January 2016 and on November 14, 2016, we announced positive clinical data from this study after two 18-week courses of treatment as compared to placebo. On January 30, 2017, we announced the FDA has granted the Company an end of phase 2 meeting to discuss the phase 3 requirements for Proellex in the treatment of uterine fibroids. Subsequently, on April 10, 2017, the Company announced that it had a meeting with the FDA to discuss the progress and next steps in the development of Proellex® for the treatment of uterine fibroids. Shortly before the meeting, the Company was notified that the meeting would be a type C/guidance meeting, rather than a type B/end of phase 2 meeting as previously anticipated. At the meeting, the FDA confirmed that Proellex® will continue on the current partial clinical hold while they consult with liver experts within the FDA regarding previously disclosed effects on the liver. Further, the FDA agreed to accept additional information from the Company and its panel of liver experts for consideration by the FDA’s internal advisory liver team. On July 17, 2017, the Company announced that it received preliminary feedback from the FDA on the oral Proellex® clinical development program. The Proellex^® program will remain on partial clinical hold, and based upon the FDA’s review of all the existing liver function safety data, the FDA has indicated that the Company will be required to compile a large pre-approval safety data base to support future development.

Vaginal Administration

We are assessing vaginal administration of Proellex® to avoid first pass liver effects and achieve higher reproductive tract concentrations of the drug while minimizing systemic exposure. We reported results from two in vivo animal studies which confirmed reduced maximum circulating concentrations of the drug when administered vaginally, as well as efficacy signals at substantially lower doses than oral administration. The Company has an active IND for the vaginal delivery of Proellex® for the treatment of uterine fibroids. Since the clinical hold relates only to the oral delivery of Proellex®, this IND has no clinical hold issues. In the first quarter of 2012, we initiated a Phase 2 vaginal administration study for the treatment of uterine fibroids. In January 2013, we reported the final study results which indicated the 12 mg dose achieved statistically significant improvement in menstrual bleeding, uterine fibroid symptoms and reduction in fibroid volume even with the low number of subjects enrolled into the study (n=12 @ 12 mg). Based on these findings, the Company believes the 12 mg dose is appropriate for further development. We held an end of Phase 2 meeting with the FDA in May 2013, to discuss a Phase 3 study design for the vaginally delivered Proellex as a treatment for uterine fibroids. The FDA recommended that a Phase 2B study should be conducted prior to commencing a Phase 3 program. On December 29, 2014, we announced that we have initiated a Phase 2B study for vaginally delivered Proellex® in the treatment of uterine fibroids. This study was fully enrolled in January 2016 and on November 14, 2016, we announced positive clinical data from this study after two 18-week courses of treatment as compared to placebo. In light of the FDA guidance on the oral Proellex® development program, the Company is assessing increasing its focus on the vaginal delivery of Proellex®.

Enclomiphene

Product Overview

We are developing enclomiphene, a single isomer of clomiphene citrate which is an orally active proprietary small molecule compound. Enclomiphene is for the treatment of secondary hypogonadism in overweight men wishing to restore normal testicular function. Men with secondary hypogonadism exhibit low testosterone levels due to under stimulated testes but they are generally fertile. Enclomiphene is designed to treat the underlying mechanism, insufficient stimulation of the testes by the pituitary, which causes secondary hypogonadism. Secondary hypogonadism due to being overweight or obese is the single greatest cause of hypogonadism in general.

Testosterone is an important male hormone. Testosterone deficiency in men is linked to several negative physical and mental conditions, including loss of muscle tone, reduced sexual desire and deterioration of memory and certain other cognitive functions. Testosterone production normally decreases as men age and this decline can be accelerated by obesity, sometimes leading to testosterone deficiency. The leading therapy for low testosterone is AndroGel®, a commercially available testosterone replacement marketed by AbbVie Inc. (“AbbVie”) for the treatment of low testosterone, which we believe has had and continues to have significant sales in North America.

Based on our own clinical trial screening data, we believe over 70% of men that have low testosterone suffer from secondary hypogonadism, a pituitary defect which is characterized by suboptimal levels of LH (luteinizing hormone) and FSH (follicle stimulating hormone). LH and FSH are the pituitary hormones that stimulate testicular testosterone and sperm production, respectively. Men with secondary hypogonadism can be readily distinguished from those that have primary testicular failure via assessment of the levels of secretions of pituitary hormones, as men with primary testicular failure experience elevated secretions of pituitary hormones. In secondary hypogonadism, the low levels of LH and FSH fail to provide adequate hormone signaling to the testes, causing testosterone levels to drop to a level where we believe pituitary secretions fall under the influence of estrogen, which is enhanced in obese men, thus further suppressing the testicular stimulation from the pituitary.

Enclomiphene acts centrally to restore testicular function and, hence, normal testosterone in the body. The administration of exogenous testosterone can restore serum testosterone levels, but does not restore testicular function and thereby generally leads to the cessation of, or significant reduction in, sperm production. Enclomiphene, by contrast, restores levels of both LH and FSH, which stimulate testicular testosterone and sperm production, respectively.

Treatment for Secondary Hypogonadism in Men Wishing to Preserve Testicular Function (Reproductive Status)

On November 8, 2010, we held a Type B meeting with the FDA to discuss whether the FDA would review our protocols for a Phase 3 trial of enclomiphene in men with secondary hypogonadism under an SPA. In the meeting, the FDA recommended that a Phase 2B study in men with secondary hypogonadism but naïve to testosterone treatment be conducted if we desired the protocols to be reviewed under an SPA. The FDA further opined that such Phase 2B study would provide for a more solid data base for design of Phase 3 studies and eventual approval of such studies under an SPA.

We completed the Phase 2B trial which consisted of four arms; placebo, two doses of enclomiphene and topical testosterone. In this study, at baseline the men exhibited morning testosterone less than 250 ng/dl and there was no statistical difference between the groups in testosterone at baseline. At the end of the three month dosing period, median morning testosterone levels were placebo, 196 ng/dl, 12.5 mg enclomiphene, 432 ng/dl, 25 mg enclomiphene, 416 ng/dl and Testim®, 393 ng/dl. A comparison of final median morning testosterone in all three of the active arms to placebo showed them to be highly statistically different and there was no statistical difference observed between these active arms. This trial also showed that enclomiphene was able to maintain sperm counts in men being treated for their low testosterone levels, whereas Testim® resulted in suppressed sperm levels.

On July 9, 2012, we announced that we reached an agreement with the FDA for the design of the pivotal efficacy studies for enclomiphene for the treatment of secondary hypogonadism. The pivotal studies were conducted under an SPA. On March 27, 2013, we announced that the top-line results from our first pivotal Phase 3 study, ZA-301, met both co-primary endpoints mandated by the FDA and we announced on September 16, 2013, that we met both co-primary endpoints in the second pivotal study, ZA-302.

The 500 subject, six month, open label safety study, ZA-300, completed enrollment in February 2013 at 28 U.S. clinical sites. On September 16, 2013, we reported top-line results of this study. Additionally, we completed enrollment into a one year, 150 subject DEXA study, ZA-303, in January 2013 at 10 U.S. clinical sites. On October 21, 2014, we announced that this study identified no new safety signals, including no evidence of negative effects on bone mineral density.

On October 22, 2013, we announced that we received guidance from the FDA instructing the Company to request a meeting to discuss the adequacy of studies ZA-301 and ZA-302. In addition to this guidance, the FDA further noted they would allow us to run head-to-head studies against approved testosterone replacement products. These head-to-head studies, ZA-304 and ZA-305, were initiated in January 2014 and subsequently completed in September and August 2014, respectively. Both of these head-to-head studies achieved superiority for both co-primary endpoints and most secondary endpoints as compared to the approved testosterone replacement product.

On February 2, 2015, we announced that we electronically submitted our NDA to the FDA for enclomiphene. The FDA accepted the NDA for review on April 1, 2015 and later assigned a PDUFA goal date of November 30, 2015. In addition, the Division of the FDA scheduled an advisory committee meeting to review the NDA for November 3, 2015. However, the Division subsequently cancelled the scheduled advisory committee meeting due to questions that arose late in the review regarding the bioanalytical method validation that could affect interpretability of certain pivotal study data. On December 1, 2015, we announced that we had received a CRL from the FDA. A CRL informs companies that an NDA cannot be approved in its present form. In the CRL, the FDA stated that, based on recent scientific developments, the design of the enclomiphene Phase 3 studies is no longer adequate to demonstrate clinical benefit and recommended that Repros conduct an additional Phase 3 study or studies to support approval in the target population. The FDA also noted concerns regarding study entry criteria, titration and bioanalytical method validation in the Phase 3 program. Subsequently, on February 4, 2016, the Company attended a meeting with the FDA reviewers and senior leaders to discuss resolution of issues identified during the NDA review. The meeting covered a broad range of topics surrounding the NDA data as well as emerging agency and expert thinking regarding the treatment of hypogonadism. The Company believes based on the meeting that the FDA is not closed to considering secondary hypogonadism as an indication. Additionally, in January 2016, the Company initiated a Phase 2 double-blind, placebo controlled, proof of concept study, ZA-205, in obese secondary hypogonadal men to assess the impact of enclomiphene on metabolic parameters and quality of life under a diet and exercise regimen. This study was fully enrolled in February 2016 and on August 15, 2016, we reported six month interim results from this study.

Business Strategy

The Company is assessing increasing its focus on the vaginal delivery of Proellex® in the treatment of uterine fibroids. We anticipate that our current liquidity will be sufficient to continue the development of our product candidates (to the extent we deem appropriate) and meet our obligations as they become due through the end of 2017. We continue to explore potential additional financing alternatives, including corporate partnering opportunities, that would provide sufficient funds to enable us to continue to develop our two product candidates through FDA approval; however, there can be no assurance that we will be successful in raising any such additional funds on a timely basis or at all.

Corporate Information

We were organized as a Delaware corporation in August 1987. Our principal executive offices are located at 2408 Timberloch Place, Suite B-7, The Woodlands, Texas, 77380, and our telephone number is (281) 719-3400. We maintain an internet website at www.reprosrx.com. The information on our website or any other website is not incorporated by reference into this quarterly report and does not constitute a part of this quarterly report. Our Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K and all amendments to such reports are made available free of charge through the Investor Relations section of our website as soon as reasonably practicable after they have been filed or furnished with the Securities and Exchange Commission.

General

We currently have six full-time employees. We utilize the services of contract research organizations, contract manufacturers and various consultants to assist us in performing clinical and regulatory services for the clinical development of our products. We are substantially dependent on our various contract groups to adequately perform the activities required to obtain regulatory approval of our products.

We have accumulated net operating losses through September 30, 2017 and the value of the tax asset associated with these accumulated net operating losses may be substantially diminished in value due to various tax regulations, including change in control provisions in the tax code. Additionally, during 2013, the Company completed an analysis of its section 382 limit. Based on this analysis, the Company concluded that the amount of net operating loss (“NOL”) carryforwards and the credits available to offset taxable income is limited under section 382. See “Critical Accounting Policies and the Use of Estimates – Income Taxes,” below.

Losses have resulted principally from costs incurred in conducting clinical trials for our product candidates, in research and development activities related to efforts to develop our products and from the associated administrative costs required to support those efforts. There can be no assurance that we will be able to successfully complete the transition from a development stage company to the successful introduction of commercially viable products. Our ability to achieve profitability will depend on, among other things, successfully completing the clinical development of our products in a reasonable time frame and at a reasonable cost, obtaining regulatory approvals, establishing marketing, sales and manufacturing capabilities or collaborative arrangements with others that possess such capabilities, and, if applicable, continuing to raise sufficient funds to finance our activities. There can be no assurance that we will be able to achieve profitability.

Critical Accounting Policies and the Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Accrued Expenses

We estimate accrued expenses as part of our process of preparing financial statements. Examples of areas in which subjective judgments may be required include costs associated with services provided by contract organizations for clinical trials, preclinical development and manufacturing of clinical materials. We accrue for costs incurred as the services are being provided by monitoring the status of the trials or services provided and the invoices received from our external service providers. In the case of clinical trials, a portion of the estimated cost normally relates to the projected cost to treat a patient in our trials, and we recognize this cost over the estimated term of the study based on the number of patients enrolled in the trial on an ongoing basis, beginning with patient enrollment. As actual costs become known to us, we adjust our accruals. To date, our estimates have not differed significantly from the actual costs incurred. However, subsequent changes in estimates may result in a material change in our accruals, which could also materially affect our balance sheet and results of operations.

Research and Development Expenses

Research and development, or R&D, expenses include salaries and related employee expenses, contracted regulatory affairs activities, insurance coverage for clinical trials and prior product sales, contracted research and consulting fees, facility costs and internal research and development supplies. We expense research and development costs in the period they are incurred. These costs consist of direct and indirect costs associated with specific projects as well as fees paid to various entities that perform research on our behalf.

Warrant Liability

In May 2017, we sold shares of common stock and pre-funded Series C Warrants to purchase common stock in an underwritten public offering which also included the issuance of Series A and Series B Warrants to purchase common stock. Due to a net cash settlement feature at the option of the warrant holder in each of the Series A and Series B warrants, the warrants are classified as liabilities under the caption “Warrant liability” in the accompanying balance sheets and recorded at estimated fair value at issuance with any subsequent change in fair value of the outstanding warrants since issuance reflected in “Change in fair value of warrant liability” in the accompanying statements of operations. Additionally, any share settlement of the Warrant liability upon a warrant exercise is reflected as a noncash settlement of the pro-rata share of the Warrant liability and issuance of common stock.

We used the Monte Carlo simulation valuation method to estimate the fair value of the outstanding Series A and Series B warrants. The Monte Carlo simulation valuation method utilizes the quoted market price of the Company’s common stock, expected volatility of the Company’s stock, no dividend yield, an expected life based on the remaining contractual term of the outstanding warrants and a risk-free interest rate. The risk-free interest rate is based on USD overnight indexed swaps with a maturity equivalent to the warrants’ expected life.

Stock-Based Compensation

We had one stock-based compensation plan at September 30, 2017, the 2011 Equity Incentive Plan. Accounting for stock-based compensation generally requires the recognition of the cost of employee services for stock-based compensation based on the grant date fair value of the equity or liability instruments issued. We use the Black-Scholes option pricing model to estimate the fair value of our stock options. Expected volatility is determined using historical volatilities based on historical stock prices for a period equal to the expected term. The expected volatility assumption is adjusted if future volatility is expected to vary from historical experience. The expected term of options represents the period of time that options granted are expected to be outstanding and falls between the options' vesting and contractual expiration dates. The Company’s historical stock option exercise experience does not provide a reasonable basis upon which to estimate expected term. As such, the simplified method was used to calculate the expected term. The risk-free interest rate is based on the yield at the date of grant of a zero-coupon U.S. Treasury bond whose maturity period equals the option's expected term.

Income Taxes

Our losses from inception to date have resulted principally from costs incurred in conducting clinical trials and in research and development activities related to efforts to develop our products and from the associated administrative costs required to support those efforts. We have recorded a deferred tax asset for our NOLs; however, as the Company has incurred losses since inception, and since there is no certainty of future profits, a valuation allowance has been provided in full on our deferred tax assets in the accompanying consolidated financial statements. Additionally, during 2013, the Company completed an analysis of its section 382 limit. Based on this analysis, the Company concluded that the amount of NOL carryforwards and the credits available to offset taxable income is limited under section 382. Accordingly, if the Company generates taxable income in any year in excess of its then annual limitation, the Company may be required to pay federal income taxes even though it has unexpired NOL carryforwards. Additionally, because U.S. tax laws limit the time during which NOLs and tax credit carryforwards may be applied against future taxable income and tax liabilities, the Company may not be able to take full advantage of its NOLs and tax credit carryforwards for federal income tax purposes. Future public and private stock placements may create additional limitations on the Company’s NOLs, credits and other tax attributes.

Changes in Accounting Policies

New Accounting Pronouncements Not Yet Adopted

Results of Operations

Comparison of the three and nine month periods ended September 30, 2017 and 2016

Revenues and Other Income

Total revenues and other income increased to $304,000 for the three month period ended September 30, 2017 as compared to $10,000 for the same period in the prior year. Total revenues and other income increased to $158,000 for the nine month period ended September 30, 2017 as compared to $41,000 for the same period in the prior year. The increase in revenues and other income in both periods is primarily due the change in the fair value of the warrants issued by the Company in May 2017 during the three and nine month periods ended September 30, 2017. Excluding the change in the fair value of the warrants, revenues and other income decreased in both periods primarily due to lower cash balances during the three and nine month periods ended September 30, 2017, as compared to the comparable periods in the prior year.

Research and Development Expenses

R&D expenses include contracted services relating to our clinical product development activities which include preclinical studies, clinical trials, expenses associated with our patent portfolio, regulatory affairs, including FDA filing fees, and bulk manufacturing scale-up activities and bulk active ingredient purchases for preclinical and clinical trials primarily relating to our two products in clinical development, which are Proellex® and enclomiphene. Research and development expenses also include internal operating expenses relating to our general research and development activities. R&D expenses decreased 69%, or $2.2 million, to $1.0 million for the three month period ended September 30, 2017, as compared to $3.2 million for the same period in the prior year. Our primary R&D expenses for the three month periods ended September 30, 2017 and 2016 are shown in the following table (in thousands):

	Three months ended September 30,
Research and Development	2017		2016		Variance			Change (%)
Proellex® clinical development	$	85	$	769	$	(684	)		(89	)%
Enclomiphene clinical development		201		992		(791	)		(80	)%
Payroll and benefits		188		663		(475	)		(72	)%
Operating and occupancy		505		758		(253	)		(33	)%
Total	$	979	$	3,182	$	(2,203	)		(69	)%

The clinical development expenses related to Proellex® decreased for the three month period ended September 30, 2017, as compared to the prior year period, due to decreased expenses associated with of our completed Phase 2b clinical trials for the treatment of uterine fibroids and endometriosis. The clinical development expenses related to enclomiphene decreased for the three month period ended September 30, 2017, as compared to the prior year period, due to decreased expenses associated with our completed Phase 2 proof of concept study, ZA-205.

Payroll and benefits expenses decreased 72%, or approximately $475,000, to $188,000 for the three month period ended September 30, 2017, as compared to $663,000 for the same period in the prior year. Salaries for the three month period ended September 30, 2017 were $140,000 as compared to $414,000 for the same period in the prior year. Also during the three month period ended September 30, 2017, the Company incurred $33,000 in severance expense related to a reduction in its workforce. As a result of the Company’s reduction in workforce during 2017, non-cash stock-based compensation decreased $170,000 for the three month period ended September 30, 2017, as compared to the same period in the prior year.

Operating and occupancy expenses decreased 33%, or approximately $253,000, to $505,000 for the three month period ended September 30, 2017 as compared to $758,000 for the same period in the prior year, primarily due to decreased legal expenses.

R&D expenses decreased 59%, or approximately $6.0 million, to $4.2 million for the nine month period ended September 30, 2017, as compared to $10.2 million for the same period in the prior year. Our primary R&D expenses for the nine month periods ended September 30, 2017 and 2016 are shown in the following table (in thousands):

	Nine months ended September 30,
Research and Development	2017		2016		Variance			Change (%)
Proellex® clinical development	$	733	$	2,915	$	(2,182	)		(75	)%
Enclomiphene clinical development		742		3,173		(2,431	)		(77	)%
Payroll and benefits		1,395		2,085		(690	)		(33	)%
Operating and occupancy		1,322		2,018		(696	)		(34	)%
Total	$	4,192	$	10,191	$	(5,999	)		(59	)%

For the nine month period ended September 30, 2017, as compared to the same period in 2016, R&D expenses related to the clinical development of Proellex® decreased 75%, or approximately $2.2 million, primarily due to decreased expenses associated with our completed Phase 2b clinical trials for the treatment of uterine fibroids and endometriosis. R&D expenses related to the clinical development of enclomiphene decreased 77%, or approximately $2.4 million, due to decreased expenses associated with our completed Phase 2 proof of concept study, ZA-205.

Payroll and benefits expenses decreased 33%, or approximately $690,000, to $1.4 million for the nine month period ended September 30, 2017, as compared to $2.1 million for the same period in the prior year. Salaries for the nine month period ended September 30, 2017 were $905,000, as compared to $1.3 million for the same period in the prior year. Included in payroll and benefits expense is a charge for non-cash stock-based compensation of $85,000 for the nine month period ended September 30, 2017, as compared to a charge of $527,000 for the same period in the prior year. Also during the nine month period ended September 30, 2017, the Company incurred $203,000 in severance expense related to a reduction in its workforce.

Operating and occupancy expenses decreased 34%, or approximately $696,000, to $1.3 million for the nine month period ended September 30, 2017, as compared to $2.0 million for the same period in the prior year, primarily due to decreased legal expenses and other outside services.

Through September 30, 2017 we have incurred approximately $72.1 million for the development of Proellex® and approximately $74.3 million for the development of enclomiphene. These accumulated costs exclude any internal operating expenses and expenses associated with the patent portfolio.

General and Administrative Expenses

General and administrative (“G&A”) expenses decreased 6%, or approximately $57,000, to $940,000 for the three month period ended September 30, 2017 as compared to $997,000 for the same period in the prior year. Our primary G&A expenses for the three month periods ended September 30, 2017 and 2016 are shown in the following table (in thousands):

	Three months ended September 30,
General and Administrative	2017		2016		Variance			Change (%)
Payroll and benefits	$	385	$	587	$	(202	)		(34	)%
Operating and occupancy		555		410		145			35	%
Total	$	940	$	997	$	(57	)		(6	)%

G&A payroll and benefits expenses include salaries, bonuses, non-cash stock-based compensation expense, fringe benefits, recruiting fees and severance pay. Included in payroll and benefits expense is a charge for non-cash stock-based compensation of $130,000 for the three month period ended September 30, 2017 as compared to a charge of $296,000 for the same period in the prior year. Additionally, salaries for the three month period ended September 30, 2017 were $229,000 as compared to $257,000 for the same period in the prior year.

G&A operating and occupancy expenses, which include expenses to operate as a public company, increased 35%, or approximately $145,000, to $555,000 for the three month period ended September 30, 2017 as compared to $410,000 for the same period in the prior year primarily due to an increase in professional fees.

G&A expenses increased 81%, or approximately $2.5 million, to $5.7 million for the nine month period ended September 30, 2017, as compared to $3.1 million for the same period in the prior year. Our primary G&A expenses for the nine month periods ended September 30, 2017 and 2016 are shown in the following table (in thousands):

	Nine months ended September 30,
General and Administrative	2017		2016		Variance		Change (%)
Payroll and benefits	$	4,248	$	1,843	$	2,405		130	%
Operating and occupancy		1,441		1,301		140		11	%
Total	$	5,689	$	3,144	$	2,545		81	%

G&A payroll and benefits expenses include salaries, bonuses, non-cash stock-based compensation expense, severance pay, recruiting fees and fringe benefits. Included in payroll and benefits expense is a charge for non-cash stock-based compensation of $595,000 for the nine month period ended September 30, 2017, as compared to a charge of $963,000 for the same period in the prior year. Additionally, salaries for the nine month period ended September 30, 2017 were $698,000, as compared to $771,000 for the same period in the prior year. Also included in payroll and benefits for the nine month period ended September 30, 2017, was a charge of $2.8 million related to the departure of Mr. Podolski.

G&A operating and occupancy expenses, which include expenses to operate as a public company, increased approximately $140,000 to $1.4 million for the nine month period ended September 30, 2017, as compared to $1.3 million for the same period in the prior year primarily due to an increase in consulting fees and other outside services.

Change in Fair Value of Warrant Liability

As a result of the May Public Offering (described in Note 6 to the financial statements included herein), the Company issued Series A, Series B and Series C warrants that include a net cash settlement feature at the option of the warrant holder in certain limited circumstances in which the Company fails to timely deliver registered common shares upon a warrant exercise. Through September 30, 2017, 2,397,834 Series B warrants and all Series C warrants have been exercised. The outstanding Series A and Series B warrants are classified as liabilities under the caption “Warrant liability” in the accompanying balance sheets and recorded at estimated fair value at issuance with any subsequent change in fair value of the outstanding warrants since issuance reflected in “Change in fair value of warrant liability” in the accompanying statements of operations. For a detailed discussion on the change in fair value of warrant liability, see Note 7 to the financial statements included herein.

Off-Balance Sheet Arrangements

As of September 30, 2017, we did not have any off-balance sheet arrangements.

Liquidity and Capital Resources

Since our inception, we have financed our operations primarily with proceeds from private placements and public offerings of equity securities and with funds received under collaborative agreements.

Our primary use of cash to date has been in operating activities to fund research and development, including preclinical studies and clinical trials, and general and administrative expenses. We had cash and cash equivalents of approximately $1.8 million as of September 30, 2017 as compared to $8.7 million as of December 31, 2016. All cash and cash equivalents as of September 30, 2017 and December 31, 2016 were held in an account backed by U.S. government securities.

Net cash of approximately $8.5 million and $12.5 million was used in operating activities during the nine month periods ended September 30, 2017 and 2016, respectively. The major use of cash for operating activities for the nine month period ended September 30, 2017 was to fund our clinical development programs and associated administrative costs. No cash was used in investing activities during the nine month periods ended September 30, 2017 and 2016. Cash provided by financing activities for the nine month period ended September 30, 2017 was approximately $3.5 million primarily from sale of 2,744,125 shares of common stock and pre-funded Series C Warrants to purchase up to 2,245,875 shares of common stock in the May Public Offering at an offering price of $0.50 per share, net of related underwriting discounts and commissions and other offering costs and the sale of 849,157 ATM Shares at a weighted average share price of $1.20, net of related offering costs.

We have experienced negative cash flows from operations since inception. We will require substantial funds for R&D, including preclinical studies and clinical trials of our product candidates, and to commence sales and marketing efforts, if appropriate, if the FDA or other regulatory approvals are obtained. We anticipate that our current liquidity will be sufficient to continue the development of our product candidates (to the extent we deem appropriate) and meet our obligations as they become due through the end of 2017. We continue to explore potential additional financing alternatives, including corporate partnering opportunities, that would provide sufficient funds to enable us to continue to develop our two product candidates through FDA approval; however, there can be no assurance that we will be successful in raising any such additional funds on a timely basis or at all. Our capital requirements will depend on many factors, which are discussed in detail in “Item 1A., Risk Factors” of Form 10-K for the fiscal year ended December 31, 2016. The uncertainties relating to the foregoing matters raise substantial doubt about our ability to continue as a going concern.

Our results of operations may vary significantly from quarter to quarter and year to year, and depend on, among other factors, our ability to raise additional capital on acceptable terms or at all, our ability to be successful in our clinical trials, the regulatory approval process in the United States and other foreign jurisdictions and the ability to complete strategic licenses and product development agreements. The timing of our revenues may not match the timing of our associated product development expenses. To date, R&D expenses have usually exceeded revenue in any particular period and/or fiscal year.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Interest Rate Risk. We had cash and cash equivalents of approximately $1.8 million at September 30, 2017 which is held in an account backed by U.S. government securities. Although this cash account is subject to fluctuations in interest rates and market conditions, no significant gain or loss on this account is expected to be recognized in earnings. We do not invest in derivative securities.

Item 4. Controls and Procedures

Disclosure Controls and Procedures

Based on their evaluation as of the end of the period covered by this Quarterly Report on Form 10-Q, our Principal Executive Officer and Principal Financial Officer have concluded that our disclosure controls and procedures (as defined in Rule 13a-15(e)) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), were effective as of September 30, 2017.

Changes in Internal Control over Financial Reporting

In connection with the evaluation described above, we identified no change in internal control over financial reporting that occurred during the quarter ended September 30, 2017 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II - OTHER INFORMATION

Item 1. Legal Proceedings

See Note 8 of the Notes to the Condensed Consolidated Financial Statements.

Item 1A. Risk Factors

Except as follows, there were no material changes from the risk factors previously disclosed in the registrant’s Form 10-K for the fiscal year ended December 31, 2016 in response to “Item 1A. Risk Factors” to Part I of Form 10-K.

Our inability to comply with the listing requirements of the NASDAQ Capital Market could result in our common stock being delisted, which could affect our common stock’s market price and liquidity and reduce our ability to raise capital. We have received a notification of delisting from NASDAQ and can provide no assurances that we will be able to successfully request an extension of time to regain compliance.

In addition, on June 14, 2017, the Staff notified us that the closing bid price of the common stock had, for 30 consecutive business days preceding the date of such notice, been below the $1.00 per share minimum required for continued listing on The NASDAQ Capital Market pursuant to NASDAQ Marketplace Rule 5550(a)(2) (the “Minimum Bid Price Rule”). In accordance with NASDAQ Marketplace Rule 5810(c)(3)(A), we were provided 180 calendar days, or until December 11, 2017 to regain compliance.

If by December 11, 2017 we cannot demonstrate compliance with the Minimum Bid Price Rule, we may be eligible for additional time. To qualify, the Staff will determine whether or not we meet The NASDAQ Capital Market initial listing criteria set forth in NASDAQ Marketplace Rule 5550, except for the Minimum Bid Price Rule. If we are not in compliance with the Stockholders’ Equity Rule, we do not expect to be eligible for an additional 180 day extension to meet the Minimum Bid Price Rule. At that time, the Staff may provide additional written notice that our securities will be subject to delisting. At that time, we may appeal the Staff’s determination to delist our securities to the Panel.

There can be no assurances that the Panel will grant our request for continued listing or that we will be able to evidence compliance with all applicable requirements for continued listing on The NASDAQ Capital Market within any extension of time that may be granted by the Panel. If our common stock is delisted, it could be more difficult to buy or sell our common stock and to obtain accurate quotations, and the price of our common stock could suffer a material decline. Delisting would also impair our ability to raise capital.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

None

Item 3. Defaults Upon Senior Securities.

None

Item 4. Mine Safety Disclosures.

None

Item 5. Other Information

None

Item 6. Exhibits

31.1*		Certification Pursuant to Rule 13(a)-14(a) or 15(d)-14(a) of the Exchange Act, As Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (Principal Executive Officer).

31.2*		Certification Pursuant to Rule 13(a)-14(a) or 15(d)-14(a) of the Exchange Act, As Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (Principal Financial Officer).

32.1**		Certification Furnished Pursuant to 18 U.S.C. Section 1350, As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Principal Executive Officer) (This exhibit shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section. Further, this exhibit shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended.)

32.2**		Certification Furnished Pursuant to 18 U.S.C. Section 1350, As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Principal Financial Officer) (This exhibit shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section. Further, this exhibit shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended.)

101.INS*		XBRL Instance Document

101.SCH*		XBRL Taxonomy Extension Schema Document

101.CAL*		XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF*		XBRL Taxonomy Extension Definition Linkbase Document

101.LAB*		XBRL Taxonomy Extension Label Linkbase Document

101.PRE*		XBRL Taxonomy Extension Presentation Linkbase Document

Filed herewith.

Furnished herewith.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

REPROS THERAPEUTICS INC.

Date: November 13, 2017	By:	/s/ Larry M. Dillaha, M.D.
	Larry M. Dillaha, M. D.
	President and Chief Executive Officer
	(Principal Executive Officer)

Date: November 13, 2017	By:	/s/ Katherine A. Anderson
	Katherine A. Anderson
	Chief Financial Officer
	(Principal Financial Officer)

EX-31.1 2 tv478357_ex31-1.htm EXHIBIT 31.1

EXHIBIT 31.1

I, Larry M. Dillaha, M.D., certify that:

1. I have reviewed this quarterly report of Repros Therapeutics Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Dated: November 13, 2017	By: /s/ Larry M. Dillaha, M.D.
	Larry M. Dillaha, M.D.
	President and Chief Executive Officer
	Repros Therapeutics Inc.
	(Principal Executive Officer)

EX-31.2 3 tv478357_ex31-2.htm EXHIBIT 31.2

EXHIBIT 31.2

I, Katherine A. Anderson, certify that:

1. I have reviewed this quarterly report of Repros Therapeutics Inc.;

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Dated: November 13, 2017	By: /s/ Katherine A. Anderson
	Katherine A. Anderson
	Chief Financial Officer
	Repros Therapeutics Inc.
	(Principal Financial Officer)

EX-32.1 4 tv478357_ex32-1.htm EXHIBIT 32.1

EXHIBIT 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Repros Therapeutics Inc. (the "Company") on Form 10-Q for the quarter ended September 30, 2017 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Larry M. Dillaha, M.D., Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

1. The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: November 13, 2017	By: /s/ Larry M. Dillaha, M.D.
	Larry M. Dillaha, M.D.
	President and Chief Executive Officer
	Repros Therapeutics Inc.
	(Principal Executive Officer)

A signed original of this written statement required by Section 906 has been provided to Repros and will be retained by Repros and furnished to the Securities and Exchange Commission or its staff upon request.

EX-32.2 5 tv478357_ex32-2.htm EXHIBIT 32.2

EXHIBIT 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Repros Therapeutics Inc. (the "Company") on Form 10-Q for the quarter ended September 30, 2017 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Katherine A. Anderson, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

1. The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: November 13, 2017	By: /s/ Katherine A. Anderson
	Katherine A. Anderson
	Chief Financial Officer
	Repros Therapeutics Inc.
	(Principal Financial Officer)

EX-101.INS 6 rprx-20170930.xml XBRL INSTANCE DOCUMENT 0000897075 2016-01-01 2016-09-30 0000897075 2017-01-01 2017-09-30 0000897075 2017-05-01 2017-05-23 0000897075 2017-05-23 0000897075 2016-07-01 2016-09-30 0000897075 2017-07-01 2017-09-30 0000897075 2016-09-30 0000897075 2017-09-30 0000897075 2017-11-07 0000897075 2016-12-31 0000897075 2015-12-31 0000897075 us-gaap:CommonStockMember 2016-12-31 0000897075 us-gaap:AdditionalPaidInCapitalMember 2016-12-31 0000897075 us-gaap:TreasuryStockMember 2016-12-31 0000897075 us-gaap:RetainedEarningsMember 2016-12-31 0000897075 us-gaap:CommonStockMember 2015-12-31 0000897075 us-gaap:AdditionalPaidInCapitalMember 2015-12-31 0000897075 us-gaap:TreasuryStockMember 2015-12-31 0000897075 us-gaap:RetainedEarningsMember 2015-12-31 0000897075 us-gaap:CommonStockMember 2017-09-30 0000897075 us-gaap:AdditionalPaidInCapitalMember 2017-09-30 0000897075 us-gaap:TreasuryStockMember 2017-09-30 0000897075 us-gaap:RetainedEarningsMember 2017-09-30 0000897075 us-gaap:CommonStockMember 2016-09-30 0000897075 us-gaap:AdditionalPaidInCapitalMember 2016-09-30 0000897075 us-gaap:TreasuryStockMember 2016-09-30 0000897075 us-gaap:RetainedEarningsMember 2016-09-30 0000897075 us-gaap:CommonStockMember 2017-01-01 2017-09-30 0000897075 us-gaap:AdditionalPaidInCapitalMember 2017-01-01 2017-09-30 0000897075 us-gaap:TreasuryStockMember 2017-01-01 2017-09-30 0000897075 us-gaap:RetainedEarningsMember 2017-01-01 2017-09-30 0000897075 us-gaap:CommonStockMember 2016-01-01 2016-09-30 0000897075 us-gaap:AdditionalPaidInCapitalMember 2016-01-01 2016-09-30 0000897075 us-gaap:TreasuryStockMember 2016-01-01 2016-09-30 0000897075 us-gaap:RetainedEarningsMember 2016-01-01 2016-09-30 0000897075 rprx:LadenburgThalmannCoIncMember 2016-08-09 0000897075 rprx:LadenburgThalmannCoIncMember 2016-08-01 2016-08-09 0000897075 us-gaap:CommonStockMember 2017-05-01 2017-05-23 0000897075 rprx:MayPublicOfferingMember us-gaap:CommonStockMember 2017-05-23 0000897075 rprx:MayPublicOfferingMember rprx:SeriesCWarrentMember 2017-05-23 0000897075 rprx:MayPublicOfferingMember rprx:SeriesWarrentMember 2017-05-23 0000897075 rprx:MayPublicOfferingMember rprx:SeriesBWarrentMember 2017-05-23 0000897075 rprx:PresidentAndCeoMember 2017-09-30 0000897075 us-gaap:MaximumMember 2017-09-30 0000897075 us-gaap:MaximumMember 2016-09-30 0000897075 us-gaap:WarrantMember 2017-01-01 2017-09-30 0000897075 rprx:PresidentAndCeoMember us-gaap:EmployeeStockOptionMember 2017-01-30 2017-02-01 0000897075 us-gaap:ChiefFinancialOfficerMember us-gaap:EmployeeStockOptionMember 2017-01-30 2017-02-01 0000897075 us-gaap:DirectorMember us-gaap:EmployeeStockOptionMember 2017-02-10 2017-02-13 0000897075 us-gaap:BoardOfDirectorsChairmanMember us-gaap:RestrictedStockUnitsRSUMember 2017-02-10 2017-02-13 0000897075 rprx:TwoThousandAndElevenEquityIncentivePlanMember 2017-01-01 2017-09-30 0000897075 us-gaap:CommonStockMember rprx:LadenburgThalmannCoIncMember 2017-01-01 2017-09-30 0000897075 rprx:LadenburgThalmannCoIncMember 2017-01-01 2017-09-30 0000897075 rprx:MayPublicOfferingMember rprx:SeriesCWarrentMember 2017-05-23 0000897075 rprx:MayPublicOfferingMember rprx:SeriesBWarrantMember 2017-05-23 0000897075 rprx:SeriesWarrentMember 2017-01-01 2017-09-30 0000897075 rprx:SeriesBWarrentMember 2017-01-01 2017-09-30 0000897075 rprx:SeriesCWarrentMember 2017-01-01 2017-09-30 0000897075 rprx:SeriesWarrentMember 2017-09-30 0000897075 rprx:SeriesBWarrentMember 2017-09-30 0000897075 rprx:SeriesCWarrentMember 2017-09-30 0000897075 rprx:SeriesWarrentMember 2016-12-31 0000897075 rprx:SeriesBWarrentMember 2016-12-31 0000897075 rprx:SeriesCWarrentMember 2016-12-31 0000897075 us-gaap:FairValueMeasurementsRecurringMember 2017-09-30 0000897075 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2017-09-30 0000897075 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2017-09-30 0000897075 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2017-09-30 0000897075 us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000897075 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2016-12-31 0000897075 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2016-12-31 0000897075 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2016-12-31 0000897075 rprx:UndesignatedPreferredStockMember 2016-12-31 0000897075 rprx:UndesignatedPreferredStockMember 2017-09-30 0000897075 rprx:MayPublicOfferingMember 2017-05-01 2017-05-23 0000897075 us-gaap:BoardOfDirectorsChairmanMember us-gaap:EmployeeStockOptionMember 2017-09-01 2017-09-15 0000897075 rprx:MayPublicOfferingMember rprx:SeriesCWarrentMember 2017-05-01 2017-05-23 0000897075 rprx:SeriesBWarrantMember us-gaap:SubsequentEventMember 2017-11-01 2017-11-13 0000897075 rprx:SeriesBWarrantMember us-gaap:SubsequentEventMember 2017-11-13 0000897075 us-gaap:FairValueInputsLevel2Member rprx:SeriesWarrantMember 2016-12-31 0000897075 us-gaap:FairValueInputsLevel2Member rprx:SeriesBWarrantMember 2016-12-31 0000897075 us-gaap:FairValueInputsLevel2Member 2016-12-31 0000897075 us-gaap:FairValueInputsLevel2Member rprx:SeriesWarrantMember 2017-01-01 2017-09-30 0000897075 us-gaap:FairValueInputsLevel2Member rprx:SeriesBWarrantMember 2017-01-01 2017-09-30 0000897075 us-gaap:FairValueInputsLevel2Member 2017-01-01 2017-09-30 0000897075 us-gaap:FairValueInputsLevel2Member rprx:SeriesWarrantMember 2017-09-30 0000897075 us-gaap:FairValueInputsLevel2Member rprx:SeriesBWarrantMember 2017-09-30 0000897075 us-gaap:FairValueInputsLevel2Member 2017-09-30 0000897075 us-gaap:WeightedAverageMember 2017-09-30 0000897075 rprx:SeriesAndBWarrantsMember 2017-09-30 0000897075 rprx:PrefundedSeriesCWarrentsMember 2017-09-30 0000897075 rprx:PrefundedSeriesCWarrentsMember 2017-01-01 2017-09-30 0000897075 rprx:SeriesCWarrentMember 2017-09-30 0000897075 rprx:SeriesWarrentMember 2016-01-01 2016-09-30 0000897075 us-gaap:WeightedAverageMember 2016-09-30 0000897075 rprx:MayPublicOfferingMember rprx:SeriesCWarrentMember 2017-05-01 2017-05-23 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure

8688000

1813000

66000

135000

8754000

2864000

3000

8757000

3783000

1880000

1246000

779000

1192000

2438000

26000

40000

326981000

329305000

3783000

1380000

6098000

-1287000

8757000

-329252000

-319529000

2659000

916000

919000

916000

5070000

2659000

1716000

9000

10000

23000

41000

304000

10000

158000

41000

940000

997000

5689000

3144000

1919000

4179000

9881000

13335000

-1615000

-4169000

-9723000

-13294000

-0.04

-0.17

-0.32

-0.55

37598000

24495000

30797000

24372000

37598000

24495000

30797000

24372000

979000

3182000

4192000

10191000

18567000

26000

326981000

-1380000

-319529000

24000

322179000

-1380000

-302256000

25938602

112350

24430461

112350

8358000

40000

329305000

-1380000

-329252000

25000

325263000

-1380000

-315550000

39602157

112350

25239134

112350

680000

1491000

1021000

1000

1020000

849157

-9723000

-13294000

-1210000 3000 -1213000 0 0 2744125 1279000 2000 1277000 0 0 2245875 568000 8000 560000 0 0 7719958 0 0 0 0 0 44440 0

60000

1333

4000

3000

1491000

680000

-609000

696000

-12482000

-8549000

1594000

3509000

-10888000

-5040000

8688000

21393000

3648000

10505000

-135000

70000

74000

3507000 1594000

2000

-568000 0 0.03

10000000

2744125

0.60

2500000

2245875

0.60

3742500

0.84

2495000

0.92

329300000

3400000

1800000

10505000

3648000

10505000

174000 27000 512000 1045000

93000

120000

916000 0

916000

37598

24495

30797

24372

2698082

2792357

3839666

50000

10000

50000

40000

424835

849157

1021000

1.2

32000

2500000

0.60

2495000

0.92

3742500 2495000 2245875 0 0 2245875

3742500

97166

0 2397834 0

-2245875 -7719958

1813000

1835000 1835000 0 0

1716000

8688000

0.0146

0.0199

0.858

1.173

10-Q false 2017-09-30 2017 Q3 REPROS THERAPEUTICS INC. 0000897075 --12-31 Smaller Reporting Company RPRX 39555133

0.001

5000000

849157

1.20

0.001

75000000

39602157

25938602

39489807

25826252

112350

Each share of common stock and each pre-funded Series C Warrant to purchase a share of common stock were sold together with a Series A Warrant to purchase 0.75 share of common stock and a Series B Warrant to purchase 0.50 share of common stock.

-295000

P3Y

P12M

$0.60 of which was pre-funded at closing and $0.001 was payable upon exercise The Series A warrants are exercisable, subject to certain limitations, upon issuance and expire five years from issuance and the Series B and Series C warrants are exercisable, subject to certain limitations, upon issuance and expire two years from issuance. The Series A and Series B warrants contain anti-dilution provisions that reduce the exercise price of the warrants if certain dilutive issuances occur, subject to a floor of $0.17 per share. Each of the warrants contain a cashless exercise provision in the event there is no effective registration statement covering the shares to be issued upon exercise of the warrants and a net cash settlement feature at the option of the warrant holder in certain limited circumstances in which the Company fails to timely deliver registered common shares upon a warrant exercise. Additionally, beginning 30 days after the issuance date, a Series B warrant holder is permitted to effect a cashless exercise and receive a net number of shares equal to the product of (i) 200% of the applicable warrant exercise percentage of the initial warrant amount and (ii) the quotient obtained by dividing (a) the difference obtained by subtracting (x) the market price, from (y) the initial exercise price of the Series B Warrants by (b) the market price (the Net Number Cashless Exercise).

1000

1593000

1594000

13833

59771

0.001

807340

1831000

588000

2419000

0 568000 568000

134000

1000

135000

1697000

19000

1716000

P3Y3M18D

P4Y7M6D

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><b><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">NOTE 1  Organization, Operations, Liquidity and Recent Developments</font></b></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><b><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></b></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Repros Therapeutics Inc. (the “Company,” “RPRX,” “Repros,” or “we,” “us” or “our”) was organized on August 20, 1987. We are a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">We are developing Proellex®, an orally administered selective blocker of the progesterone receptor in women, for the treatment of uterine fibroids and endometriosis. Uterine fibroids and endometriosis affect millions of women of reproductive age. Proellex® has shown statistically significant results in previous Phase 2 studies for uterine fibroids and endometriosis. We completed a low dose escalating study as permitted by the Food and Drug Administration (“FDA”) in late 2011, to determine both signals of efficacy and safety for low oral doses of the drug. There was no evidence of elevations of liver enzymes over baseline, suggesting these lower doses avoid the type of adverse events seen at much higher doses in earlier studies. On March 17, 2014, we announced that the FDA indicated that we may proceed to conduct Phase 1 and Phase 2 studies of low dose oral Proellex® for uterine fibroids and endometriosis while remaining on partial clinical hold. This guidance indicated that the highest allowed dose will be 12 mg daily. On December 29, 2014, we announced that we have initiated a Phase 2B study for low dose oral Proellex® in the treatment of uterine fibroids. This study was fully enrolled in January 2016 and on November 14, 2016, we announced positive clinical data from this study after two 18-week courses of treatment as compared to placebo. On April 10, 2017, the Company announced that it had a meeting with the FDA to discuss the progress and next steps in the development of Proellex® for the treatment of uterine fibroids. Shortly before the meeting, the Company was notified that the meeting would be a type C/Guidance meeting, rather than a type B/End of phase 2 meeting as previously anticipated. At the meeting, the FDA confirmed that Proellex® will continue on the current partial clinical hold while they consult with liver experts within the FDA regarding previously disclosed effects on the liver. On July 17, 2017, the Company announced that it received preliminary feedback from the FDA on the oral Proellex® clinical development program. The Proellex<sup style="font-style:normal">®</sup> program will remain on partial clinical hold, and based upon the FDA’s review of all the existing liver function safety data, the FDA has indicated that the Company will be required to compile a large pre-approval safety data base to support future development.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The Company has an active Investigational New Drug Application (“IND”) for the vaginal delivery of Proellex® for the treatment of uterine fibroids. Since the clinical hold relates only to oral delivery of Proellex®, this IND has no clinical hold issues. In the first quarter of 2012, we initiated a Phase 2 vaginal administration study for the treatment of uterine fibroids and subsequently reported the final study results in January 2013. We held an end of Phase 2 meeting with the FDA in May 2013, to discuss a Phase 3 study design for vaginally delivered Proellex as a treatment for uterine fibroids. The FDA recommended that a Phase 2B study should be conducted prior to commencing a Phase 3 program. On December 29, 2014, we announced that we have initiated a Phase 2B study for vaginally delivered Proellex® in the treatment of uterine fibroids. This study was fully enrolled in January 2016 and on November 14, 2016, we announced positive clinical data from this study after two 18-week courses of treatment as compared to placebo. In light of the FDA guidance on the oral Proellex® development program, the Company is assessing increasing its focus on the vaginal delivery of Proellex®.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">We are also developing enclomiphene, a single isomer of clomiphene citrate which is an orally active proprietary small molecule compound. Enclomiphene is for the treatment of secondary hypogonadism in overweight men wishing to restore normal testicular function. Men with secondary hypogonadism exhibit low testosterone levels due to under stimulated testes but they are generally fertile. Enclomiphene is designed to treat the underlying mechanism, insufficient stimulation of the testes by the pituitary, which causes secondary hypogonadism. Secondary hypogonadism due to being overweight or obese is the single greatest cause of hypogonadism in general.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">On February 2, 2015, we announced that we electronically submitted our New Drug Applications (“NDA”) to the FDA for enclomiphene. The FDA accepted the NDA for review on April 1, 2015 and later assigned a Prescription Drug User Fee (“PDUFA”) goal date of November 30, 2015. In addition, the Division of Bone, Reproductive and Urologic Products (the “Division”) of the FDA scheduled an advisory committee meeting to review the NDA for November 3, 2015. However, the Division subsequently cancelled the scheduled advisory committee meeting due to questions that arose late in the review regarding the bioanalytical method validation that could affect interpretability of certain pivotal study data. On December 1, 2015, we announced that we had received a Complete Response Letter (“CRL”) from the FDA. A CRL informs companies that an NDA cannot be approved in its present form. In the CRL, the FDA stated that, based on recent scientific developments, the design of the enclomiphene Phase 3 studies is no longer adequate to demonstrate clinical benefit and recommended that Repros conduct an additional Phase 3 study or studies to support approval in the target population. The FDA also noted concerns regarding study entry criteria, titration and bioanalytical method validation in the Phase 3 program.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> Subsequently, on February 4, 2016, the Company attended a meeting with the FDA reviewers and senior leaders to discuss resolution of issues identified during the NDA review. The meeting covered a broad range of topics surrounding the NDA data as well as emerging agency and expert thinking regarding the treatment of hypogonadism. The Company believes based on the meeting that the FDA is not closed to considering secondary hypogonadism as an indication. Additionally, in January 2016, the Company initiated a Phase 2 double-blind, placebo controlled, proof of concept study, ZA-205, in obese secondary hypogonadal men to assess the impact of enclomiphene on metabolic parameters and quality of life under a diet and exercise regimen. This study was fully enrolled in February 2016 and on August 15, 2016, we reported six month interim results from this study.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> Additionally, on September 12, 2016, we reported that we successfully submitted a European centralized marketing authorization application (“MAA”) for enclomiphene for the treatment of secondary hypogonadism. This MAA was subsequently accepted by the European Medicines Agency (“EMA”) which, as previously reported, has assigned the United Kingdom as the primary rapporteur and France as the co-rapporteur for the application review. As part of the ongoing review process, the Company has filed responses to the EMAs questions in the third quarter of 2017.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">On December 6, 2016, the Company participated in the industry presentation at the Bone, Reproductive and Urologic Drugs’ Advisory Committee meeting. The advisory panel provided the FDA with advice regarding a clinical and regulatory path to approval for products, such as enclomiphene, in subjects with obesity-related hypogonadism who wish to maintain spermatogenesis.  The panel voted 16 to 5 that the achievement of testosterone improvement while maintaining evidence of spermatogenesis was not sufficient, in and of itself, to provide evidence of clinical benefit. At the meeting, numerous panel members suggested that an additional endpoint related to symptoms should be assessed. </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><b><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> Liquidity</font></b></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><b><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></b></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">On August 9, 2016, we entered into an Equity Distribution Agreement (the “Equity Distribution Agreement”) with Ladenburg Thalmann & Co. Inc. (“Ladenburg”), pursuant to which we had the ability to issue and sell from time to time through Ladenburg, as sales agent and/or principal, shares of our common stock having an aggregate offering price of up to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10</font> million (the “ATM Shares”). Ladenburg had no obligation to sell on our behalf any specific number or dollar amount of the ATM Shares, but Ladenburg, upon acceptance of written instructions from us, agreed to use its commercially reasonable efforts consistent with its customary trading and sales practices, to sell the ATM Shares up to the amount specified, and otherwise in accordance with the terms of a placement notice delivered to Ladenburg. Ladenburg was entitled to receive a commission of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3</font>% of the gross sales price of all ATM Shares sold through it under the Equity Distribution Agreement. Effective May 9, 2017, the Company terminated the Sales Agreement and the related ATM Program. During the nine month period ended September 30, 2017, we sold <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 849,157</font> ATM Shares at a weighted average share price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.20</font> for proceeds of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,021,000</font>, net of expenses including approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">32,000</font> in commissions to Ladenburg.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">On May 23, 2017, the Company sold <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2,744,125</font> shares of common stock and pre-funded Series C Warrants to purchase up to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2,245,875</font> shares of common stock in an underwritten public offering to certain investors (the “May Public Offering”). Each share of common stock was sold at a price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.60</font> and each Series C Warrant was issued with an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.60</font> per share of common stock, $0.60 of which was pre-funded at closing and $0.001 was payable upon exercise. This May Public Offering also included the issuance of Series A Warrants to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 3,742,500</font> shares of our common stock at an initial exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.84</font> per share and Series B Warrants to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2,495,000</font> shares of our common stock at an initial exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.92</font> per share. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">Each share of common stock and each pre-funded Series C Warrant to purchase a share of common stock were sold together with a Series A Warrant to purchase 0.75 share of common stock and a Series B Warrant to purchase 0.50 share of common stock.</font> The net proceeds to the Company from the sale of common stock and warrants, after deducting underwriting discounts and commissions and other offering expenses, were approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2.5</font> million. For further discussion of the May Public Offering, see Note 6 to the financial statements included herein.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">As of September 30, 2017, we had accumulated losses of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">329.3</font> million, approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.8</font> million in cash and cash equivalents, and accounts payable and accrued expenses of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3.4</font> million, in the aggregate. Included in our accrued expenses is $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.8</font> million related to the accrued severance payments due Mr. Podolski upon his termination, which are anticipated to be paid in the first quarter of 2018 and 2019 with our restricted cash of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.8</font> million. We anticipate that our current liquidity will be sufficient to continue the development of our product candidates (to the extent we deem appropriate) and meet our obligations as they become due through the end of 2017. We continue to explore potential additional financing alternatives, including corporate partnering opportunities, that would provide sufficient funds to enable us to continue to develop our two product candidates through FDA approval; however, there can be no assurance that we will be successful in raising any such additional funds on a timely basis or at all. The foregoing matters raise substantial doubt about our ability to continue as a going concern.</font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b>Nasdaq Listing</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On November 8, 2017, we received written notification from the Listing Qualifications Staff (the “Staff”) of The NASDAQ Stock Market LLC (“Nasdaq”) indicating that, based upon our continued non-compliance with the minimum stockholders’ equity requirement for continued listing on The NASDAQ Capital Market, as set forth in NASDAQ Marketplace Rule 5550(b)(2) (the “Stockholders’ Equity Rule”), the Staff had determined to delist our common stock from Nasdaq (the “Staff Determination”) unless we timely request a hearing before the Nasdaq Hearings Panel (the “Panel”). We will have until November 15, 2017 to request a hearing.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">We intend to timely request a hearing before the Panel, which request will stay any suspension or delisting action by Nasdaq at least until the hearing process concludes and any extension granted by the Panel expires. At the hearing, we plan to present our plan to evidence compliance with the Stockholders’ Equity Rule, and request an extension of time within which to do so.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The November 8, 2017 notice has no immediate effect on the listing of our common stock and the common stock will continue to trade on the NASDAQ Capital Market under the symbol “RPRX” at least until the hearing process concludes and any extension granted by the Panel expires.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">There can be no assurances that the Panel will grant our request for continued listing or that we will be able to evidence compliance with all applicable requirements for continued listing on The NASDAQ Capital Market within any extension of time that may be granted by the Panel.</div> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><b><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></b></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><b><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Basis of Presentation</font></b></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><b><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></b></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">These financial statements are unaudited; however, in the opinion of management, these statements reflect all adjustments necessary for a fair statement of the results for the periods reported. All such adjustments are of a normal recurring nature unless disclosed otherwise. These financial statements, including notes, have been prepared in accordance with the applicable rules of the SEC and do not include all of the information and disclosures required by U.S. GAAP for complete financial statements.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">These interim financial statements should be read in conjunction with the financial statements and notes thereto included in our 2016 Annual Report on Form 10-K. The results of operations for the three and nine month periods ended September 30, 2017 are not necessarily indicative of the results to be expected for the full year.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><b><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Changes in Accounting Policies</font></b></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><b><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></b></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">In November 2016, the FASB issued ASU No. 2016-18, “Statement of Cash Flows (Topic 230): Restricted Cash”. The new standard requires restricted cash to be included with cash and cash equivalents when reconciling the beginning and ending amounts on the statement of cash flows, and requires additional disclosures in the notes to the financial statements. ASU 2016-18 is effective for fiscal years beginning after December 15, 2017 and interim periods within those fiscal years and early adoption is permitted. The Company adopted this standard during the quarter ended March 31, 2017. See Note 2 to the financial statements included herein.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">In March 2016, the FASB issued ASU 2016-09, CompensationStock Compensation (ASC Topic 718): Improvements to Employee Share-Based Payment Accounting. The new standard simplifies the accounting for stock-based compensation, including amendments on how both taxes related to stock-based compensation and cash payments made to taxing authorities are recorded. ASU 2016-09 is effective for annual reporting periods beginning on or after December 15, 2016, and interim periods within those annual periods and early application is permitted, with any adjustments reflected as of the beginning of the fiscal year of adoption. The Company adopted ASU 2016-09 effective January 1, 2017. The adoption of this standard did not have a material effect on the Company’s financial statements.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">In November 2015, the FASB issued ASU No. 2015-17, “Balance Sheet Classification of Deferred Taxes” (“ASU 2015-17”), which requires entities to present deferred tax assets and deferred tax liabilities as noncurrent in a classified balance sheet. The ASU simplifies the current guidance in ASC Topic 740, Income Taxes, which requires entities to separately present deferred tax assets and liabilities as current and noncurrent in a classified balance sheet. ASU 2015-17 is effective for fiscal years beginning after December 15, 2016, and interim periods within those annual periods. The Company adopted ASU 2015-07 effective January 1, 2017. The adoption of this standard did not have a material effect on the Company’s financial statements.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><b><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">New Accounting Pronouncements Not Yet Adopted</font></b></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><b><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></b></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">In July 2017, the FASB issued ASU No. 2017-11, “(Part I) Accounting or Certain Financial Instruments with Down Round Features” (“ASU 2017-11”), which changes the classification analysis of certain equity-linked financial instruments with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature will no longer preclude equity classification when assessing whether the instrument is indexed to an entity’s own stock. ASU 2017-11 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. The Company is currently evaluating the impact of this standard on its consolidated financial statements.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">In February 2016, FASB issued ASU 2016-02, Leases (ASC Topic 842), which supersedes ASC Topic 840, Leases. The new standard is intended to increase transparency and comparability of organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. The new guidance is effective for financial statements issued for annual reporting periods beginning after December 15, 2018, and early application is permitted. The Company is currently evaluating the impact of this standard on its consolidated financial statements.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">In May 2014, the FASB issued Accounting Standards Update 2014-09, “Revenue from Contracts with Customers” (“ASU 2014-09”). ASU 2014-09 is a comprehensive new revenue recognition model requiring a company to recognize revenue to depict the transfer of goods or services to a customer at an amount reflecting the consideration it expects to receive in exchange for those goods or services. In adopting ASU 2014-09, companies may use either a full retrospective or a modified retrospective approach. Additionally, this guidance requires improved disclosures regarding the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. On July 9, 2015, the FASB voted to delay the effective date of this standard by one year. This deferral resulted in ASU 2014-09 being effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017, with early adoption being permitted for annual periods beginning after December 15, 2016. Entities have the option of using either a full retrospective or a modified retrospective approach to adopt the guidance. The Company is currently assessing the effects this guidance may have on its consolidated financial statements, as well as the method of transition that the Company will use in adopting the new standard.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

1.20

32000

0.60

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><strong><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">NOTE 6  Stockholders’ Equity</font></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><strong><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><strong><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> Offerings</font></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><strong><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">On August 9, 2016, we entered into an Equity Distribution Agreement (the “Equity Distribution Agreement”) with Ladenburg Thalmann & Co. Inc. (“Ladenburg”), pursuant to which we had the ability to issue and sell from time to time through Ladenburg, as sales agent and/or principal, shares of our common stock having an aggregate offering price of up to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10</font> million (the “ATM Shares”). Ladenburg had no obligation to sell on our behalf any specific number or dollar amount of the ATM Shares, but Ladenburg, upon acceptance of written instructions from us, agreed to use its commercially reasonable efforts consistent with its customary trading and sales practices, to sell the ATM Shares up to the amount specified, and otherwise in accordance with the terms of a placement notice delivered to Ladenburg. Ladenburg was entitled to receive a commission of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3</font>% of the gross sales price of all ATM Shares sold through it under the Equity Distribution Agreement. Effective May 9, 2017, the Company terminated the Sales Agreement and the related ATM Program.</font></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">No ATM Shares were sold during the three month period ended September 30, 2017 due to the termination of the ATM program in May 2017. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The table below summarizes our ATM Shares sold during the nine month period ended September 30, 2017 (in thousands, except share and per share amounts):</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0px:auto; WIDTH: 50%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Nine Months</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Ended</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>September 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"> <div>ATM Shares sold</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>849,157</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"> <div>Weighted average share price</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.20</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"> <div>Net proceeds, net of offering costs</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,021</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"> <div>Offering commissions to Ladenburg</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>32</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">On May 23, 2017, the Company sold <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2,744,125</font> shares of common stock and pre-funded Series C Warrants to purchase up to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2,245,875</font> shares of common stock in an underwritten public offering to certain investors (the “May Public Offering”). Each share of common stock was sold at a price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.60</font> and each Series C Warrant was issued with an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.60</font> per share of common stock, <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>$0.60 of which was pre-funded at closing and $0.001 was payable upon exercise<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>. This May Public Offering also included the issuance of Series A Warrants to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 3,742,500</font> shares of our common stock at an initial exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.84</font> per share and Series B Warrants to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2,495,000</font> shares of our common stock at an initial exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.92</font> per share.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> Each share of common stock and each pre-funded Series C Warrant to purchase a share of common stock were sold together with a Series A Warrant to purchase 0.75 share of common stock and a Series B Warrant to purchase 0.50 share of common stock.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> The net proceeds to the Company from the sale of common stock and warrants, after deducting underwriting discounts and commissions and other offering expenses, were approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2.5</font> million.</font></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>The Series A warrants are exercisable, subject to certain limitations, upon issuance and expire five years from issuance and the Series B and Series C warrants are exercisable, subject to certain limitations, upon issuance and expire two years from issuance. The Series A and Series B warrants contain anti-dilution provisions that reduce the exercise price of the warrants if certain dilutive issuances occur, subject to a floor of $0.17 per share. Each of the warrants contain a cashless exercise provision in the event there is no effective registration statement covering the shares to be issued upon exercise of the warrants and a net cash settlement feature at the option of the warrant holder in certain limited circumstances in which the Company fails to timely deliver registered common shares upon a warrant exercise. Additionally, beginning 30 days after the issuance date, a Series B warrant holder is permitted to effect a cashless exercise and receive a net number of shares equal to the product of (i) 200% of the applicable warrant exercise percentage of the initial warrant amount and (ii) the quotient obtained by dividing (a) the difference obtained by subtracting (x) the market price, from (y) the initial exercise price of the Series B Warrants by (b) the market price (the “Net Number Cashless Exercise”).<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Due to the net cash settlement feature at the option of the warrant holder discussed above, the Series A and Series B warrants are classified as liabilities under the caption “Warrant liability” in the accompanying balance sheets and recorded at estimated fair value at issuance with any subsequent change in fair value of the outstanding warrants since issuance reflected in “Change in fair value of warrant liability” in the accompanying statements of operations. Additionally, any share settlement of the warrant liability upon a warrant exercise is reflected as a noncash settlement of the pro-rata share of the warrant liability and issuance of common stock. See Note 7 to the financial statements included herein for discussion regarding the fair value of the warrants.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>The following table reflects the warrant activity of the Company for the nine month period ended September 30, 2017:</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Shares of</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Series A</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Series B</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Series C</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Common Stock</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Warrants</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Warrants</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Warrants</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Issued</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Balance, December 31, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Issuance of warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3,742,500</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,495,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,245,875</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Series C Warrants exercised to purchase common stock for cash at $0.001 per share</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(2,245,875)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,245,875</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Net Number Cashless Exercise of Series B Warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(2,397,834)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>7,719,958</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Balance, September 30, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>3,742,500</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>97,166</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Through November 13, 2017, an additional <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 13,833</font> Series B Warrants were exercised under the cashless alternative provision and as a result the Company has issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 59,771</font> shares of common stock.</font></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">On July 24, 2017, the Company filed a shelf registration statement on Form S-3 (File No. 333-219428, the “July 2017 Registration Statement”) to permit the continued exercise of the Series A Warrants and Series B Warrants following the expiration, on that date, of the Company’s prior Registration Statement on Form S-3, as amended (File No. 333-197253). The July 2017 Registration Statement was declared effective by the SEC on August 4, 2017. Between the expiration of the prior registration statement and the effectiveness of the July 2017 Registration Statement, exercises of the Series A Warrants and Series B Warrants continued to be permitted under the prior registration statement pursuant to Rule 415(a)(5) under the Securities Act of 1933, as amended.</font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

508000

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The table below summarizes our ATM Shares sold during the nine month period ended September 30, 2017 (in thousands, except share and per share amounts):</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0px:auto; WIDTH: 50%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Nine Months</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Ended</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>September 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"> <div>ATM Shares sold</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>849,157</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"> <div>Weighted average share price</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.20</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"> <div>Net proceeds, net of offering costs</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,021</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"> <div>Offering commissions to Ladenburg</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>32</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The following table reflects the warrant activity of the Company for the nine month period ended September 30, 2017:</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Shares of</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Series A</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Series B</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Series C</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Common Stock</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Warrants</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Warrants</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Warrants</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Issued</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Balance, December 31, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Issuance of warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3,742,500</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,495,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,245,875</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Series C Warrants exercised to purchase common stock for cash at $0.001 per share</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(2,245,875)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,245,875</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Net Number Cashless Exercise of Series B Warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(2,397,834)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>7,719,958</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Balance, September 30, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>3,742,500</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>97,166</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The table below presents our assets and liabilities that are measured at fair value on a recurring basis at September 30, 2017 and are categorized using the fair value hierarchy (in thousands):</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Total</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Level 1</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Level 2</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Level 3</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Cash and cash equivalents</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,813</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,813</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Restricted cash</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,835</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,835</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Warrant liability</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(1,716)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(1,716)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The table below presents our assets and liabilities that are measured at fair value on a recurring basis at December 31, 2016 and are categorized using the fair value hierarchy (in thousands):</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Total</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Level 1</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Level 2</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Level 3</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Cash and cash equivalents</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>8,688</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>8,688</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

0.001

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The following summarizes the change in the Warrant liability for the nine months ended September 30, 2017 (in thousands):</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Series A</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Series B</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Warrants</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Warrants</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Total</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>Warrant liability at date of issue</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>(1,831)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>(588)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>(2,419)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>Share settlement due to warrant exercises</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>568</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>568</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>Change in fair value</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>134</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>135</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>Warrant liability at September 30, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>(1,697)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>(19)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>(1,716)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><strong><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">NOTE 7  Fair Value Measurements</font></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><strong><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The FASB has established a framework for measuring fair value in generally accepted accounting principles. That framework provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurements) and the lowest priority to unobservable inputs (level 3 measurements). The three levels of the fair value hierarchy are described as follows:</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 36.7pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> Level 1.</font></i> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 36.7pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 36.7pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> Level 2.</font></i> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  Inputs to the valuation methodology include:</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 36.7pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <table style="LINE-HEIGHT: 107%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" width="96"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt"> ⋅</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Quoted prices for similar assets or liabilities in active markets</font></div> </td> </tr> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> </td> </tr> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Quoted prices for identical or similar assets or liabilities in inactive markets</font></div> </td> </tr> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> </td> </tr> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt"> ⋅</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Inputs other than quoted prices that are observable for the asset or liability</font></div> </td> </tr> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> </td> </tr> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt"> ⋅</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Inputs that are derived principally from or corroborated by observable market data by correlation or other means</font></div> </td> </tr> </table> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 0.5in; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 0.5in; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">If the asset or liability has a specified (contractual) term, the level 2 input must be observable for substantially the full term of the asset or liability.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 0.5in; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 0.5in; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> Level 3.</font></i> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  Inputs to the valuation methodology are unobservable and significant to the fair value measurement.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 0.5in; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The asset or liability’s fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques used need to maximize the use of observable inputs and minimize the use of unobservable inputs.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>The table below presents our assets and liabilities that are measured at fair value on a recurring basis at September 30, 2017 and are categorized using the fair value hierarchy (in thousands):</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Total</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Level 1</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Level 2</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Level 3</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Cash and cash equivalents</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,813</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,813</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Restricted cash</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,835</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,835</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Warrant liability</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(1,716)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(1,716)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The table below presents our assets and liabilities that are measured at fair value on a recurring basis at December 31, 2016 and are categorized using the fair value hierarchy (in thousands):</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Total</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Level 1</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Level 2</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Level 3</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Cash and cash equivalents</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>8,688</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>8,688</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">All cash and cash equivalents and restricted cash as of September 30, 2017 and December 31, 2016 were held in accounts backed by U.S. government securities.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">On May 23, 2017, as a result of the May Public Offering (described in Note 6 to the financial statements included herein), the Company issued Series A, Series B and Series C warrants that include a net cash settlement feature at the option of the warrant holder in certain limited circumstances in which the Company fails to timely deliver registered common shares upon a warrant exercise. All Series C warrants were exercised in June 2017. The Series A and Series B warrants are classified as liabilities under the caption “Warrant liability” in the accompanying balance sheets and recorded at estimated fair value at issuance with any subsequent change in fair value of the outstanding warrants since issuance reflected in “Change in fair value of warrant liability” in the accompanying statements of operations. The fair value of the Series A and Series B warrant liability at the issue date was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2,419,000</font> after giving effect to anti-dilution adjustments under the assumption that the anti-dilution mechanism contained in the Series A and Series B warrants was in effect. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The following summarizes the change in the Warrant liability for the nine months ended September 30, 2017 (in thousands):</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Series A</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Series B</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Warrants</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Warrants</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Total</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>Warrant liability at date of issue</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>(1,831)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>(588)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>(2,419)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>Share settlement due to warrant exercises</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>568</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>568</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>Change in fair value</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>134</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>135</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>Warrant liability at September 30, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>(1,697)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>(19)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>(1,716)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The Company will continue to adjust the Warrant liability for changes in fair value of the outstanding warrants until the earlier of the exercise of the warrants, modification of the warrants, or expiration of the warrants.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The fair value of the Company’s warrant liability recorded in the Company’s financial statements was determined using the Monte Carlo simulation valuation method with the quoted market price of the Company’s common stock, expected volatility of the Company’s stock, no dividend yield, an expected life based on the remaining contractual term of the outstanding warrants and a risk-free interest rate based on USD overnight indexed swaps with a maturity equivalent to the warrants’ expected life.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>The Company calculated the estimated fair value of the Series A and Series B warrants on the issuance date and at September 30, 2017 using the following weighted average assumptions:</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Issue Date</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>(May 23, 2017)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>September 30, 2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Risk-free interest rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1.46</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1.99</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Contractual term</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3.3 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>4.6 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Expected volatility</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>85.8</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>117.3</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

2397834

1333

0.01

2.15

$0.60 of which was pre-funded at closing and $0.001 was payable upon exercise

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Accrued expenses consist of the following (in thousands):</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="60%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>September 30, 2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>December 31, 2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div>Current accrued expenses:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div>Personnel related costs</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,045</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>512</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div>Research and development costs</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>27</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>174</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div>Other</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>120</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>93</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div>Total current accrued expenses</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,192</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>779</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div>Long-term accrued expenses:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div>Accrued severance</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>916</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div>Total long-term accrued expenses</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>916</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

5000

2419000

EX-101.SCH 7 rprx-20170930.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink 102 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:definitionLink link:calculationLink 103 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 104 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:definitionLink link:calculationLink 105 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY link:presentationLink link:definitionLink link:calculationLink 106 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 107 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:definitionLink link:calculationLink 108 - Disclosure - Organization, Operations, Liquidity and Recent Developments link:presentationLink link:definitionLink link:calculationLink 109 - Disclosure - Cash, Cash Equivalents and Restricted Cash link:presentationLink link:definitionLink link:calculationLink 110 - Disclosure - Accrued Expenses link:presentationLink link:definitionLink link:calculationLink 111 - Disclosure - Loss Per Share link:presentationLink link:definitionLink link:calculationLink 112 - Disclosure - Stock-Based Compensation link:presentationLink link:definitionLink link:calculationLink 113 - Disclosure - Stockholders’ Equity link:presentationLink link:definitionLink link:calculationLink 114 - Disclosure - Fair Value Measurements link:presentationLink link:definitionLink link:calculationLink 115 - Disclosure - Commitments and Contingencies link:presentationLink link:definitionLink link:calculationLink 116 - Disclosure - Organization, Operations, Liquidity and Recent Developments (Policies) link:presentationLink link:definitionLink link:calculationLink 117 - Disclosure - Cash, Cash Equivalents and Restricted Cash (Tables) link:presentationLink link:definitionLink link:calculationLink 118 - Disclosure - Accrued Expenses (Tables) link:presentationLink link:definitionLink link:calculationLink 119 - Disclosure - Loss Per Share (Tables) link:presentationLink link:definitionLink link:calculationLink 120 - Disclosure - Stockholders’ Equity (Tables) link:presentationLink link:definitionLink link:calculationLink 121 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:definitionLink link:calculationLink 122 - Disclosure - Organization, Operations, Liquidity and Recent Developments (Additional Information) (Details) link:presentationLink link:definitionLink link:calculationLink 123 - Disclosure - Cash, Cash Equivalents and Restricted Cash (Details) link:presentationLink link:definitionLink link:calculationLink 124 - Disclosure - Cash, Cash Equivalents and Restricted Cash (Additional Information) (Details) link:presentationLink link:definitionLink link:calculationLink 125 - Disclosure - Accrued Expenses (Details) link:presentationLink link:definitionLink link:calculationLink 126 - Disclosure - Loss Per Share (Calculation of Loss Per Share) (Details) link:presentationLink link:definitionLink link:calculationLink 127 - Disclosure - Loss Per Share (Additional Information) (Details) link:presentationLink link:definitionLink link:calculationLink 128 - Disclosure - Stock-Based Compensation (Additional Information) (Details) link:presentationLink link:definitionLink link:calculationLink 129 - Disclosure - Stockholders’ Equity (Details) link:presentationLink link:definitionLink link:calculationLink 130 - Disclosure - Stockholders’ Equity (Details 1) link:presentationLink link:definitionLink link:calculationLink 131 - Disclosure - Stockholder's Equity (Additional information) (Details) link:presentationLink link:definitionLink link:calculationLink 132 - Disclosure - Fair Value Measurements (Details) link:presentationLink link:definitionLink link:calculationLink 133 - Disclosure - Fair Value Measurements (Details 1) link:presentationLink link:definitionLink link:calculationLink 134 - Disclosure - Fair Value Measurements (Details 2) link:presentationLink link:definitionLink link:calculationLink 135 - Disclosure - Fair Value Measurements (Additional Information) (Details) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 8 rprx-20170930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 rprx-20170930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 rprx-20170930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information [Abstract] Document Information [Table] Class of Stock [Axis] Accounts Payable and Accrued Liabilities, Current [Abstract] Accounts Payable and Accrued Liabilities Disclosure [Text Block] Accrued Expenses Earnings Per Share [Abstract] Earnings Per Share [Text Block] Loss Per Share Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Stock-Based Compensation Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Schedule of Accrued Liabilities [Table Text Block] Accrued Expenses Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Calculation of Loss Per Share Organization, Consolidation and Presentation of Financial Statements [Abstract] Schedule of Product Information [Table] Legal Entity [Axis] Entity [Domain] Sale of Stock [Axis] Sale of Stock [Domain] Subsequent Event Type [Axis] Development Stage Enterprise Deficit Accumulated During Development Stages Deficit accumulated during the development stage Cumulative net losses reported during the development stage. Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Cash and cash equivalents Statement of Financial Position [Abstract] Statement [Table] Class of Stock [Domain] Statement [Line Items] Assets [Abstract] ASSETS Assets, Current [Abstract] Current assets Restricted Cash and Cash Equivalents, Current Restricted cash Restricted cash, current Property, Plant and Equipment, Net Fixed assets, net Net Fixed Assets Restricted Cash and Cash Equivalents, Noncurrent Non-current restricted cash Restricted cash, noncurrent Liabilities and Equity [Abstract] LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities, Current [Abstract] Current liabilities Accounts Payable, Current Accounts payable Accrued Liabilities, Current Accrued expenses Total current accrued expenses Liabilities, Current Total current liabilities Liabilities, Noncurrent [Abstract] Long-term liabilities Commitments and Contingencies Commitment & Contingencies (note 8) Preferred Stock Value Undesignated Preferred Stock, $.001 par value, 5,000,000 shares authorized, none issued and outstanding Common Stock Value Common Stock, $.001 par value, 75,000,000 shares authorized, 39,602,157 and 25,938,602 shares issued, respectively; 39,489,807 and 25,826,252 shares outstanding, respectively, as of September 30, 2017 and December 31, 2016 Additional Paid in Capital, Total Additional paid-in capital Treasury Stock Value Cost of treasury stock, 112,350 shares Retained Earnings (Accumulated Deficit) Accumulated deficit Accumulated deficit Stockholders Equity Attributable to Parent, Total Total stockholders' equity Balance Shareholders’ Equity Total stockholders’ equity Balance Stockholders Equity [Abstract] Stockholders' Equity Schedule Of Accrued Liabilities [Table] Schedule of Accrued Liabilities [Table] Schedule Of Accrued Liabilities [Line Items] Schedule of Accrued Liabilities [Line Items] Accrued Personnel Expense Current Personnel related costs Accrued Personnel Expense Current Accrued Research and Development Expense Current Research and development costs Accrued Research and Development Expense, Current Other Accrued Liabilities Current Other Net Income (Loss) Attributable to Parent, Total Net loss Net loss Net loss Weighted Average Number Of Shares Outstanding, Basic and Diluted Average common shares outstanding Shares used in loss per share calculation Earnings Per Share, Basic and Diluted, Total Basic and diluted loss per share Loss per share - basic and diluted Net loss per share - basic and diluted Loss per share - basic and diluted Earnings Per Share Disclosure [Table] Range [Axis] Class of Warrant or Right, Number of Securities Called by Warrants or Rights Anti-dilutive shares of common stock excluded from computation of earning per share Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Plan Name [Axis] Plan Name [Domain] Two Thousand And Eleven Equity Incentive Plan [Member] 2011 Equity Incentive Plan Member Domain plan member Vesting [Axis] Vesting [Domain] Related Party [Axis] Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Stock Options, Granted Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Stock Options, Forfeited/cancelled Undesignated Preferred Stock [Member] Preferred Stock, Par or Stated Value Per Share Preferred Stock, par value Preferred Stock Shares Authorized Preferred Stock, shares authorized Preferred Stock Shares Issued Preferred Stock, issued Preferred Stock Shares Outstanding Preferred Stock, outstanding Common Stock, Par or Stated Value Per Share Common Stock, par value Common Stock Shares Authorized Common Stock, shares authorized Common Stock, Shares, Issued Common Stock, shares issued Common Stock, Shares, Outstanding Common Stock, shares outstanding Treasury Stock Shares Treasury stock, shares Income Statement [Abstract] Revenues [Abstract] Revenues and other income Investment Income, Interest Interest income Fair Value Adjustment of Warrants Change in fair value of warrant liability Change in fair value of warrant liability Change in fair value Revenues, Total Total revenues and other income Total revenues and other income Costs and Expenses [Abstract] Expenses Expenses: Research and Development Expense, Total Research and development Research and development General and Administrative Expense, Total General and administrative General and Administrative Weighted Average Number Of Shares Outstanding [Abstract] Shares used in loss per share calculation: Weighted Average Number of Shares Outstanding, Basic, Total Basic Weighted average common shares outstanding Weighted Average Number of Shares Outstanding, Diluted Diluted Weighted Average Number of Shares Outstanding, Diluted Statement Of Stockholders' Equity [Abstract] Equity Components [Axis] Equity Component [Domain] Common Stock [Member] Common Stock [Member] Additional Paid-in Capital [Member] Additional Paid-in Capital [Member] Treasury Stock [Member] Treasury Stock [Member] Shares, Issued Balance (in shares) Balance (in shares) Adjustments To Additional Paid In Capital, Share-Based Compensation, Stock Options, Requisite Service Period Recognition Stock based compensation Stock Issued During Period, Value, Other Issuance of 849,157 shares of common stock pursuant to the Equity Distribution Agreement at a weighted average price of $1.20, net of offering costs of $32 Issuance [Axis] Eequity issuances [Domain] Range [Domain] Auction Market Preferred Securities, Stock Series [Axis] Statement Of Cash Flows [Abstract] Net Cash Provided By Used In Operating Activities [Abstract] Cash Flows from Operating Activities Depreciation, Depletion and Amortization, Nonproduction, Total Depreciation Share-based Compensation, Total Noncash stock-based compensation Increase (Decrease) in Prepaid Expense and Other Assets, Total Increase in prepaid expenses and other current assets Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Net Cash Provided By Used In Investing Activities [Abstract] Cash Flows from Investing Activities Payments to Acquire Property, Plant, and Equipment, Total Capital expenditures Net Cash Provided by (Used in) Investing Activities, Total Net cash used in investing activities Net cash used in investing activities Net Cash Provided By Used In Financing Activities [Abstract] Cash Flows from Financing Activities Proceeds from Issuance of Common Stock and Warrants Issuance of common stock and warrants, net of offering costs The cash inflow from the additional capital contribution through the issuance of common stock and warrants to the entity. Proceeds from Warrant Exercises Proceeds from exercise of stock warrants Cash and Cash Equivalents, Period Increase (Decrease), Total Net decrease in cash, cash equivalents and restricted cash Organization Consolidation and Presentation Of Financial Statements Disclosure [Text Block] Organization, Operations, Liquidity and Recent Developments Accounts Payable and Accrued Liabilities, Current Accounts payable and accrued expenses Class of Warrant or Right [Axis] Auction Market Preferred Securities, Stock Series, Title [Domain] Retained Earnings [Member] Accumulated Deficit [Member] Stock Issued During Period, Shares, Other Issuance of 849,157 shares of common stock pursuant to the Equity Distribution Agreement at a weighted average price of $1.20, net of offering costs of $32 (in shares) Stock And Pre-funded Series Warrants Issued During Period, Value Issuance of 2,744,125 shares of common stock at $0.60 per share, Series A and Series B warrants, and pre-funded Series C warrants at $0.60 per share in the May Public Offering, net of offering costs of $508 Value of shares of stock and pre-funded series c Warrants issued attributable to transactions. Maximum [Member] Title of Individual [Axis] Related Party [Domain] Net Cash Provided by (Used in) Operating Activities, Total Net cash used in operating activities Net cash used in operating activities Shares Issued, Price Per Share Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs Ladenburg Thalmann Co Inc [Member] Ladenburg Thalmann Co. Inc [Member] Commission Revenue percentage Represent percentage of commission on sales revenue. Proceeds from Issuance Initial Public Offering Stock Issued During Period, Shares, New Issues Issuance of 807,340 shares of common stock at a weighted average price of $2.15, net of offering costs of $1450 (in shares) ATM Shares sold Proceeds from Issuance of Common Stock Net proceeds, net of offering costs Subsequent Event Type [Domain] Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Assets Total assets Total assets Liabilities and Equity, Total Total liabilities and stockholders' equity Due to Employees, Noncurrent Accrued severance Derivative Liability, Noncurrent Warrant liability Assets, Current Total current assets Stock And Pre-funded Series Warrants Issued During Period, Shares Issuance of 2,744,125 shares of common stock at $0.60 per share, Series A and Series B warrants, and pre-funded Series C warrants at $0.60 per share in the May Public Offering, net of offering costs of $508 (in shares) Number of shares and Pre-funded Series C Warrants of stock issued attributable to transactions. Shares Issued Upon Exercise of Series C warrant, Value Exercise of 2,245,875 Series C Warrants to purchase common stock for cash at $0.001 per share Value of shares issued during the period upon exercise of Series C warrants. Shares Issued Upon Exercise of Series C warrant, Shares Exercise of 2,245,875 Series C Warrants to purchase common stock for cash at $0.001 per share (in shares) Number of shares issued during the period upon exercise of Series C warrants. Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Issuance of 60,000 shares of restricted common stock (in shares) Stock Issued During Period, Shares, For Vested Restricted Stock Units Issuance of 44,440 shares of common stock for vested RSUs (in shares) Number of shares issued during the period related to vesting of restricted stock units. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash, cash equivalents and restricted cash at beginning of period Cash, cash equivalents and restricted cash at end of period Cash and Cash Equivalents [Abstract] Cash and Cash Equivalents Disclosure [Text Block] Cash, Cash Equivalents and Restricted Cash Schedule of Cash and Cash Equivalents [Table Text Block] Schedule of Cash and Cash Equivalents Cash, Cash Equivalents, and Short-term Investments Total Restricted Cash and Cash Equivalents Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Award Type [Axis] Relationship to Entity [Domain] President And CEO [Member] Option Indexed to Issuer's Equity [Axis] Equity Award [Domain] Board of Directors Chairman [Member] Restricted Stock Units (RSUs) [Member] Chief Financial Officer [Member] Director [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Option Indexed to Issuer's Equity, Type [Domain] Employee Stock Option [Member] Liquidity [Policy Text Block] Liquidity Disclosure of accounting policy for liquidity of equity instrument. Securities Exchange Listing [Policy Text Block] Nasdaq Listing Disclosure of accounting policies for securities exchange listing policy. Basis of Accounting, Policy [Policy Text Block] Basis of Presentation Employee-related Liabilities Accrued Liabilities, Current [Abstract] Current accrued expenses: Accounts Payable and Accrued Liabilities, Noncurrent [Abstract] Long-term accrued expenses: Accrued Severance Noncurrent Accrued severance Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due after one year related to severance. Accounts Payable and Accrued Liabilities, Noncurrent Total long-term accrued expenses Liabilities Total liabilities Stock Issued Upon Cashless Exercise Of Series B Warrants,Value Net Number Cashless Exercise of 2,397,834 Series B Warrants to purchase common stock (share settlement of Warrant liability) Value of shares issued during the period upon cashless exercise of warrants. Stock Issued Upon Cashless Exercise Of Series B Warrants,Shares Net Number Cashless Exercise of 2,397,834 Series B Warrants to purchase common stock (share settlement of Warrant liability) (in shares) Number of shares issued during the period upon cashless exercise of warrants. Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures Issuance of 60,000 shares of restricted common stock Stock Issued During Period, Value, For Vested Restricted Stock Units Issuance of 44,440 shares of common stock for vested RSUs Value of stock related to vested Restricted Stock units issued during the period. Stock Issued During Period, Value, Stock Options Exercised Exercise of 1,333 Series A warrants to purchase common stock for cash at $0.01 per share Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Exercise of 1,333 Series A warrants to purchase common stock for cash at $0.01 per share (in shares) Stock Issued During Period, Value, New Issues Issuance of 807,340 shares of common stock at a weighted average price of $2.15, net of offering costs of $1450 Class of Warrant or Right [Domain] Pre-funded Series C Warrents [Member] Series C Warrent [Member] Series A Warrent [Member] Class of Warrant or Right, Exercise Price of Warrants or Rights Warrants, exercise price per share Stock Issued, Shares Upon Cashless Exercise Of Series B Warrants Number of shares issued during the period upon cashless exercise of warrants. Shares Issued Upon Exercise of Series A warrant, Shares Number of shares issued during the period upon exercise of Series A warrants. Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total Increase (decrease) in accounts payable and accrued expenses Net Cash Provided by (Used in) Financing Activities, Total Net cash provided by financing activities Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Earnings Per Share Disclosure [Line Items] Earnings Per Share Disclosure [Line Items] Warrant [Member] May Public Offering [Member] EX-101.PRE 11 rprx-20170930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 12 R1.htm IDEA: XBRL DOCUMENT

Document And Entity Information - shares	9 Months Ended
Document And Entity Information - shares	Sep. 30, 2017	Nov. 07, 2017
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2017
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	Q3
Entity Registrant Name	REPROS THERAPEUTICS INC.
Entity Central Index Key	0000897075
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Trading Symbol	RPRX
Entity Common Stock, Shares Outstanding		39,555,133

XML 13 R2.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Current assets
Cash and cash equivalents	$ 1,813	$ 8,688
Restricted cash	916	0
Prepaid expenses and other current assets	135	66
Total current assets	2,864	8,754
Fixed assets, net	0	3
Non-current restricted cash	919	0
Total assets	3,783	8,757
Current liabilities
Accounts payable	1,246	1,880
Accrued expenses	1,192	779
Total current liabilities	2,438	2,659
Long-term liabilities
Accrued severance	916	0
Warrant liability	1,716	0
Total liabilities	5,070	2,659
Commitment & Contingencies (note 8)
Stockholders' Equity
Undesignated Preferred Stock, $.001 par value, 5,000,000 shares authorized, none issued and outstanding	0	0
Common Stock, $.001 par value, 75,000,000 shares authorized, 39,602,157 and 25,938,602 shares issued, respectively; 39,489,807 and 25,826,252 shares outstanding, respectively, as of September 30, 2017 and December 31, 2016	40	26
Additional paid-in capital	329,305	326,981
Cost of treasury stock, 112,350 shares	(1,380)	(1,380)
Accumulated deficit	(329,252)	(319,529)
Total stockholders' equity	(1,287)	6,098
Total liabilities and stockholders' equity	$ 3,783	$ 8,757

XML 14 R3.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Sep. 30, 2017	Dec. 31, 2016
Common Stock, par value	$ 0.001	$ 0.001
Common Stock, shares authorized	75,000,000	75,000,000
Common Stock, shares issued	39,602,157	25,938,602
Common Stock, shares outstanding	39,489,807	25,826,252
Treasury stock, shares	112,350	112,350
Undesignated Preferred Stock [Member]
Preferred Stock, par value	$ 0.001	$ 0.001
Preferred Stock, shares authorized	5,000,000	5,000,000
Preferred Stock, issued	0	0
Preferred Stock, outstanding	0	0

XML 15 R4.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Revenues and other income
Interest income	$ 9	$ 10	$ 23	$ 41
Change in fair value of warrant liability	295	0	135	0
Total revenues and other income	304	10	158	41
Expenses
Research and development	979	3,182	4,192	10,191
General and administrative	940	997	5,689	3,144
Total expenses	1,919	4,179	9,881	13,335
Net loss	$ (1,615)	$ (4,169)	$ (9,723)	$ (13,294)
Loss per share - basic and diluted	$ (0.04)	$ (0.17)	$ (0.32)	$ (0.55)
Shares used in loss per share calculation:
Basic	37,598	24,495	30,797	24,372
Diluted	37,598	24,495	30,797	24,372

XML 16 R5.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Treasury Stock [Member]	Accumulated Deficit [Member]
Balance at Dec. 31, 2015	$ 18,567	$ 24	$ 322,179	$ (1,380)	$ (302,256)
Balance (in shares) at Dec. 31, 2015		24,430,461		112,350
Stock based compensation	1,491	$ 0	1,491	$ 0	0
Exercise of 1,333 Series A warrants to purchase common stock for cash at $0.01 per share	0	$ 0	0	$ 0	0
Exercise of 1,333 Series A warrants to purchase common stock for cash at $0.01 per share (in shares)		1,333		0
Issuance of 807,340 shares of common stock at a weighted average price of $2.15, net of offering costs of $1450	1,594	$ 1	1,593	$ 0	0
Issuance of 807,340 shares of common stock at a weighted average price of $2.15, net of offering costs of $1450 (in shares)		807,340		0
Net loss	(13,294)	$ 0	0	$ 0	(13,294)
Balance at Sep. 30, 2016	8,358	$ 25	325,263	$ (1,380)	(315,550)
Balance (in shares) at Sep. 30, 2016		25,239,134		112,350
Balance at Dec. 31, 2016	6,098	$ 26	326,981	$ (1,380)	(319,529)
Balance (in shares) at Dec. 31, 2016		25,938,602		112,350
Stock based compensation	680	$ 0	680	$ 0	0
Issuance of 849,157 shares of common stock pursuant to the Equity Distribution Agreement at a weighted average price of $1.20, net of offering costs of $32	1,021	$ 1	1,020	0	0
Issuance of 849,157 shares of common stock pursuant to the Equity Distribution Agreement at a weighted average price of $1.20, net of offering costs of $32 (in shares)		849,157
Issuance of 2,744,125 shares of common stock at $0.60 per share, Series A and Series B warrants, and pre-funded Series C warrants at $0.60 per share in the May Public Offering, net of offering costs of $508	(1,210)	$ 3	(1,213)	0	0
Issuance of 2,744,125 shares of common stock at $0.60 per share, Series A and Series B warrants, and pre-funded Series C warrants at $0.60 per share in the May Public Offering, net of offering costs of $508 (in shares)		2,744,125
Exercise of 2,245,875 Series C Warrants to purchase common stock for cash at $0.001 per share	1,279	$ 2	1,277	0	0
Exercise of 2,245,875 Series C Warrants to purchase common stock for cash at $0.001 per share (in shares)		2,245,875
Net Number Cashless Exercise of 2,397,834 Series B Warrants to purchase common stock (share settlement of Warrant liability)	568	$ 8	560	0	0
Net Number Cashless Exercise of 2,397,834 Series B Warrants to purchase common stock (share settlement of Warrant liability) (in shares)		7,719,958
Issuance of 60,000 shares of restricted common stock	0	$ 0	0	$ 0	0
Issuance of 60,000 shares of restricted common stock (in shares)		60,000		0
Issuance of 44,440 shares of common stock for vested RSUs	0	$ 0	0	$ 0	0
Issuance of 44,440 shares of common stock for vested RSUs (in shares)		44,440		0
Net loss	(9,723)	$ 0	0	$ 0	(9,723)
Balance at Sep. 30, 2017	$ (1,287)	$ 40	$ 329,305	$ (1,380)	$ (329,252)
Balance (in shares) at Sep. 30, 2017		39,602,157		112,350

XML 17 R6.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (Parenthetical) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Shares Issued, Price Per Share	$ 0.60
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs	$ 32
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.01
Stock Issued, Shares Upon Cashless Exercise Of Series B Warrants	2,397,834
Common Stock [Member]
Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures	60,000
Stock Issued During Period, Shares, For Vested Restricted Stock Units	44,440
Stock Issued During Period, Shares, Other	849,157
Stock And Pre-funded Series Warrants Issued During Period, Shares	2,744,125
Shares Issued Upon Exercise of Series C warrant, Shares	2,245,875
Stock Issued During Period, Shares, New Issues		807,340
Pre-funded Series C Warrents [Member]
Shares Issued, Price Per Share	$ 0.60
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs	$ 508
Series C Warrent [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.001
Series A Warrent [Member]
Shares Issued Upon Exercise of Series A warrant, Shares		1,333
Series A and B Warrants [Member]
Shares Issued, Price Per Share	0.60
Weighted Average [Member]
Shares Issued, Price Per Share	$ 1.20	$ 2.15

XML 18 R7.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Cash Flows from Operating Activities
Net loss	$ (9,723)	$ (13,294)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	3	4
Noncash stock-based compensation	680	1,491
Change in fair value of warrant liability	(135)	0
Increase in prepaid expenses and other current assets	(70)	(74)
Increase (decrease) in accounts payable and accrued expenses	696	(609)
Net cash used in operating activities	(8,549)	(12,482)
Cash Flows from Investing Activities
Capital expenditures	0	0
Net cash used in investing activities	0	0
Cash Flows from Financing Activities
Issuance of common stock and warrants, net of offering costs	3,507	1,594
Proceeds from exercise of stock warrants	2	0
Net cash provided by financing activities	3,509	1,594
Net decrease in cash, cash equivalents and restricted cash	(5,040)	(10,888)
Cash, cash equivalents and restricted cash at beginning of period	8,688	21,393
Cash, cash equivalents and restricted cash at end of period	3,648	10,505
Noncash transactions:
Settlement of warrant liability due to cashless warrant exercises	$ (568)	$ 0

XML 19 R8.htm IDEA: XBRL DOCUMENT

Organization, Operations, Liquidity and Recent Developments

9 Months Ended

Sep. 30, 2017

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Organization, Operations, Liquidity and Recent Developments

NOTE 1 — Organization, Operations, Liquidity and Recent Developments

Liquidity

Nasdaq Listing

Basis of Presentation

Changes in Accounting Policies

New Accounting Pronouncements Not Yet Adopted

XML 20 R9.htm IDEA: XBRL DOCUMENT

Cash, Cash Equivalents and Restricted Cash

9 Months Ended

Sep. 30, 2017

Cash and Cash Equivalents [Abstract]

Cash, Cash Equivalents and Restricted Cash

NOTE 2 — Cash, Cash Equivalents and Restricted Cash

As of September 30, 2017, the Company maintained $1.8 million as restricted cash. The funds are being held in accordance with the Release Agreement entered into with Mr. Podolski on February 1, 2017.

	September 30, 2017		September 30, 2016
Cash and cash equivalents	$	1,813	$	10,505
Restricted cash, current		916		—
Restricted cash, noncurrent		919		—
Total	$	3,648	$	10,505

XML 21 R10.htm IDEA: XBRL DOCUMENT

Accrued Expenses

9 Months Ended

Sep. 30, 2017

Accounts Payable and Accrued Liabilities, Current [Abstract]

Accrued Expenses

NOTE 3 — Accrued Expenses

Accrued expenses consist of the following (in thousands):

	September 30, 2017		December 31, 2016
Current accrued expenses:
Personnel related costs	$	1,045	$	512
Research and development costs		27		174
Other		120		93
Total current accrued expenses	$	1,192	$	779

Long-term accrued expenses:
Accrued severance	$	916	$	—
Total long-term accrued expenses	$	916	$	—

XML 22 R11.htm IDEA: XBRL DOCUMENT

Loss Per Share

9 Months Ended

Sep. 30, 2017

Earnings Per Share [Abstract]

Loss Per Share

NOTE 4 — Loss Per Share

The following table presents information necessary to calculate loss per share for the three and nine month periods ended September 30, 2017 and 2016 (in thousands, except per share amounts):

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2017		2016		2017		2016
Net loss	$	(1,615)	$	(4,169)	$	(9,723)	$	(13,294)
Average common shares outstanding		37,598		24,495		30,797		24,372
Basic and diluted loss per share	$	(0.04)	$	(0.17)	$	(0.32)	$	(0.55)

XML 23 R12.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation

9 Months Ended

Sep. 30, 2017

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Stock-Based Compensation

NOTE 5 – Stock-Based Compensation

XML 24 R13.htm IDEA: XBRL DOCUMENT

Stockholders’ Equity

9 Months Ended

Sep. 30, 2017

Stockholders' Equity Note [Abstract]

Stockholders’ Equity

NOTE 6 — Stockholders’ Equity

Offerings

	Nine Months
	Ended
	September 30,
	2017

ATM Shares sold		849,157
Weighted average share price	$	1.20
Net proceeds, net of offering costs	$	1,021
Offering commissions to Ladenburg	$	32

The following table reflects the warrant activity of the Company for the nine month period ended September 30, 2017:

							Shares of
	Series A		Series B		Series C		Common Stock
	Warrants		Warrants		Warrants		Issued
Balance, December 31, 2016		—		—		—
Issuance of warrants		3,742,500		2,495,000		2,245,875
Series C Warrants exercised to purchase common stock for cash at $0.001 per share		—		—		(2,245,875)		2,245,875
Net Number Cashless Exercise of Series B Warrants		—		(2,397,834)		—		7,719,958
Balance, September 30, 2017		3,742,500		97,166		—

Through November 13, 2017, an additional 13,833 Series B Warrants were exercised under the cashless alternative provision and as a result the Company has issued 59,771 shares of common stock.

XML 25 R14.htm IDEA: XBRL DOCUMENT

Fair Value Measurements

9 Months Ended

Sep. 30, 2017

Fair Value Disclosures [Abstract]

Fair Value Disclosures [Text Block]

NOTE 7 — Fair Value Measurements

Level 1. Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets.

Level 2. Inputs to the valuation methodology include:

	⋅	Quoted prices for similar assets or liabilities in active markets

		Quoted prices for identical or similar assets or liabilities in inactive markets

	⋅	Inputs other than quoted prices that are observable for the asset or liability

	⋅	Inputs that are derived principally from or corroborated by observable market data by correlation or other means

If the asset or liability has a specified (contractual) term, the level 2 input must be observable for substantially the full term of the asset or liability.

Level 3. Inputs to the valuation methodology are unobservable and significant to the fair value measurement.

The table below presents our assets and liabilities that are measured at fair value on a recurring basis at September 30, 2017 and are categorized using the fair value hierarchy (in thousands):

	Total		Level 1		Level 2		Level 3
Cash and cash equivalents	$	1,813	$	1,813	$	—	$	—
Restricted cash	$	1,835	$	1,835	$	—	$	—
Warrant liability	$	(1,716)	$	—	$	(1,716)	$	—

The table below presents our assets and liabilities that are measured at fair value on a recurring basis at December 31, 2016 and are categorized using the fair value hierarchy (in thousands):

		Total			Level 1			Level 2			Level 3
Cash and cash equivalents		$	8,688		$	8,688		$	—		$	—

All cash and cash equivalents and restricted cash as of September 30, 2017 and December 31, 2016 were held in accounts backed by U.S. government securities.

	Series A		Series B
	Warrants		Warrants		Total
Warrant liability at date of issue	$	(1,831)	$	(588)	$	(2,419)
Share settlement due to warrant exercises		-		568		568
Change in fair value		134		1		135
Warrant liability at September 30, 2017	$	(1,697)	$	(19)	$	(1,716)

The Company calculated the estimated fair value of the Series A and Series B warrants on the issuance date and at September 30, 2017 using the following weighted average assumptions:

	Issue Date
	(May 23, 2017)			September 30, 2017
Risk-free interest rate		1.46	%		1.99	%
Contractual term		3.3 years			4.6 years
Expected volatility		85.8	%		117.3	%

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 26 R15.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

9 Months Ended

Sep. 30, 2017

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

NOTE 8 — Commitments and Contingencies

None.

XML 27 R16.htm IDEA: XBRL DOCUMENT

Organization, Operations, Liquidity and Recent Developments (Policies)

9 Months Ended

Sep. 30, 2017

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Liquidity

Liquidity

Nasdaq Listing

Nasdaq Listing

Basis of Presentation

Basis of Presentation

Changes in Accounting Policies

Changes in Accounting Policies

Recent Accounting Pronouncements

New Accounting Pronouncements Not Yet Adopted

XML 28 R17.htm IDEA: XBRL DOCUMENT

Cash, Cash Equivalents and Restricted Cash (Tables)

9 Months Ended

Sep. 30, 2017

Cash and Cash Equivalents [Abstract]

Schedule of Cash and Cash Equivalents

	September 30, 2017		September 30, 2016
Cash and cash equivalents	$	1,813	$	10,505
Restricted cash, current		916		—
Restricted cash, noncurrent		919		—
Total	$	3,648	$	10,505

XML 29 R18.htm IDEA: XBRL DOCUMENT

Accrued Expenses (Tables)

9 Months Ended

Sep. 30, 2017

Accounts Payable and Accrued Liabilities, Current [Abstract]

Accrued Expenses

Accrued expenses consist of the following (in thousands):

	September 30, 2017		December 31, 2016
Current accrued expenses:
Personnel related costs	$	1,045	$	512
Research and development costs		27		174
Other		120		93
Total current accrued expenses	$	1,192	$	779

Long-term accrued expenses:
Accrued severance	$	916	$	—
Total long-term accrued expenses	$	916	$	—

XML 30 R19.htm IDEA: XBRL DOCUMENT

Loss Per Share (Tables)

9 Months Ended

Sep. 30, 2017

Earnings Per Share [Abstract]

Calculation of Loss Per Share

The following table presents information necessary to calculate loss per share for the three and nine month periods ended September 30, 2017 and 2016 (in thousands, except per share amounts):

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2017		2016		2017		2016
Net loss	$	(1,615)	$	(4,169)	$	(9,723)	$	(13,294)
Average common shares outstanding		37,598		24,495		30,797		24,372
Basic and diluted loss per share	$	(0.04)	$	(0.17)	$	(0.32)	$	(0.55)

XML 31 R20.htm IDEA: XBRL DOCUMENT

Stockholders’ Equity (Tables)

9 Months Ended

Sep. 30, 2017

Stockholders' Equity Note [Abstract]

Schedule of Stockholders Equity

The table below summarizes our ATM Shares sold during the nine month period ended September 30, 2017 (in thousands, except share and per share amounts):

	Nine Months
	Ended
	September 30,
	2017

ATM Shares sold		849,157
Weighted average share price	$	1.20
Net proceeds, net of offering costs	$	1,021
Offering commissions to Ladenburg	$	32

Schedule Of Warrant Activity

The following table reflects the warrant activity of the Company for the nine month period ended September 30, 2017:

							Shares of
	Series A		Series B		Series C		Common Stock
	Warrants		Warrants		Warrants		Issued
Balance, December 31, 2016		—		—		—
Issuance of warrants		3,742,500		2,495,000		2,245,875
Series C Warrants exercised to purchase common stock for cash at $0.001 per share		—		—		(2,245,875)		2,245,875
Net Number Cashless Exercise of Series B Warrants		—		(2,397,834)		—		7,719,958
Balance, September 30, 2017		3,742,500		97,166		—

XML 32 R21.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Tables)

9 Months Ended

Sep. 30, 2017

Fair Value Disclosures [Abstract]

Fair Value Measurements, Recurring and Nonrecurring

The table below presents our assets and liabilities that are measured at fair value on a recurring basis at September 30, 2017 and are categorized using the fair value hierarchy (in thousands):

	Total		Level 1		Level 2		Level 3
Cash and cash equivalents	$	1,813	$	1,813	$	—	$	—
Restricted cash	$	1,835	$	1,835	$	—	$	—
Warrant liability	$	(1,716)	$	—	$	(1,716)	$	—

The table below presents our assets and liabilities that are measured at fair value on a recurring basis at December 31, 2016 and are categorized using the fair value hierarchy (in thousands):

		Total			Level 1			Level 2			Level 3
Cash and cash equivalents		$	8,688		$	8,688		$	—		$	—

Fair Value Liabilities Measured On Warrant liability

The following summarizes the change in the Warrant liability for the nine months ended September 30, 2017 (in thousands):

	Series A		Series B
	Warrants		Warrants		Total
Warrant liability at date of issue	$	(1,831)	$	(588)	$	(2,419)
Share settlement due to warrant exercises		-		568		568
Change in fair value		134		1		135
Warrant liability at September 30, 2017	$	(1,697)	$	(19)	$	(1,716)

Fair Value Measurements Estimated Warrants Issuance

The Company calculated the estimated fair value of the Series A and Series B warrants on the issuance date and at September 30, 2017 using the following weighted average assumptions:

	Issue Date
	(May 23, 2017)			September 30, 2017
Risk-free interest rate		1.46	%		1.99	%
Contractual term		3.3 years			4.6 years
Expected volatility		85.8	%		117.3	%

- Definition

Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.

+ References + Details

XML 33 R22.htm IDEA: XBRL DOCUMENT

Organization, Operations, Liquidity and Recent Developments (Additional Information) (Details) - USD ($) $ / shares in Units, $ in Thousands		1 Months Ended	9 Months Ended
	Aug. 09, 2016	May 23, 2017	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Product Information [Line Items]
Deficit accumulated during the development stage			$ 329,300
Cash and cash equivalents			1,813	$ 10,505	$ 8,688
Accounts payable and accrued expenses			$ 3,400
Shares Issued, Price Per Share			$ 0.60
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 0.01
Proceeds from Issuance of Common Stock and Warrants		$ 2,500	$ 3,507	$ 1,594
Series C Warrent [Member]
Product Information [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 0.001
Common Stock [Member]
Product Information [Line Items]
Issuance of 807,340 shares of common stock at a weighted average price of $2.15, net of offering costs of $1450 (in shares)				807,340
Stock And Pre-funded Series Warrants Issued During Period, Shares		2,744,125	2,744,125
President And CEO [Member]
Product Information [Line Items]
Employee-related Liabilities			$ 1,800
Restricted Cash			$ 1,800
May Public Offering [Member]
Product Information [Line Items]
Class of Warrant or Right,Description of Exercise Price		Each share of common stock and each pre-funded Series C Warrant to purchase a share of common stock were sold together with a Series A Warrant to purchase 0.75 share of common stock and a Series B Warrant to purchase 0.50 share of common stock.
May Public Offering [Member] \| Series C Warrent [Member]
Product Information [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.60
Class of Warrant or Right,Description of Exercise Price		$0.60 of which was pre-funded at closing and $0.001 was payable upon exercise
May Public Offering [Member] \| Series A Warrent [Member]
Product Information [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.84
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		3,742,500
May Public Offering [Member] \| Series B Warrent [Member]
Product Information [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.92
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		2,495,000
May Public Offering [Member] \| Common Stock [Member]
Product Information [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		2,245,875
Ladenburg Thalmann Co. Inc [Member]
Product Information [Line Items]
Commission Revenue percentage	3.00%
Proceeds from Issuance Initial Public Offering	$ 10,000
Issuance of 807,340 shares of common stock at a weighted average price of $2.15, net of offering costs of $1450 (in shares)			849,157
Proceeds from Issuance of Common Stock			$ 1,021
Shares Issued Weighted Average Price Per Share			$ 1.20
Payments of Stock Issuance Costs			$ 32
Ladenburg Thalmann Co. Inc [Member] \| Common Stock [Member]
Product Information [Line Items]
Issuance of 807,340 shares of common stock at a weighted average price of $2.15, net of offering costs of $1450 (in shares)			849,157
Shares Issued Weighted Average Price Per Share			$ 1.2

XML 34 R23.htm IDEA: XBRL DOCUMENT

Cash, Cash Equivalents and Restricted Cash (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016	Sep. 30, 2016
Cash and cash equivalents	$ 1,813	$ 8,688	$ 10,505
Restricted cash, current	916	0	0
Restricted cash, noncurrent	919	$ 0	0
Total	$ 3,648		$ 10,505

XML 35 R24.htm IDEA: XBRL DOCUMENT

Cash, Cash Equivalents and Restricted Cash (Additional Information) (Details) $ in Millions	Sep. 30, 2017 USD ($)
Restricted Cash and Cash Equivalents	$ 1.8

XML 36 R25.htm IDEA: XBRL DOCUMENT

Accrued Expenses (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Current accrued expenses:
Personnel related costs	$ 1,045	$ 512
Research and development costs	27	174
Other	120	93
Total current accrued expenses	1,192	779
Long-term accrued expenses:
Accrued severance	916	0
Total long-term accrued expenses	$ 916	$ 0

XML 37 R26.htm IDEA: XBRL DOCUMENT

Loss Per Share (Calculation of Loss Per Share) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Net loss	$ (1,615)	$ (4,169)	$ (9,723)	$ (13,294)
Average common shares outstanding	37,598	24,495	30,797	24,372
Basic and diluted loss per share	$ (0.04)	$ (0.17)	$ (0.32)	$ (0.55)

XML 38 R27.htm IDEA: XBRL DOCUMENT

Loss Per Share (Additional Information) (Details) - shares	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Warrant [Member]
Earnings Per Share Disclosure [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	3,839,666
Maximum [Member]
Earnings Per Share Disclosure [Line Items]
Anti-dilutive shares of common stock excluded from computation of earning per share	2,698,082	2,792,357

XML 39 R28.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation (Additional Information) (Details) - shares			1 Months Ended	9 Months Ended
	Feb. 13, 2017	Feb. 01, 2017	Sep. 15, 2017	Sep. 30, 2017
President And CEO [Member] \| Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		50,000
Board of Directors Chairman [Member] \| Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross			5,000
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period			12 months
Board of Directors Chairman [Member] \| Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	3 years
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	40,000
Chief Financial Officer [Member] \| Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period		10,000
Director [Member] \| Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	50,000
2011 Equity Incentive Plan Member
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period				424,835

XML 40 R29.htm IDEA: XBRL DOCUMENT

Stockholders’ Equity (Details) - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Common Stock [Member]
ATM Shares sold		807,340
Ladenburg Thalmann Co Inc [Member]
ATM Shares sold	849,157
Weighted average share price	$ 1.20
Net proceeds, net of offering costs	$ 1,021
Offering commissions to Ladenburg	$ 32
Ladenburg Thalmann Co Inc [Member] \| Common Stock [Member]
ATM Shares sold	849,157
Weighted average share price	$ 1.2

XML 41 R30.htm IDEA: XBRL DOCUMENT

Stockholders’ Equity (Details 1)	9 Months Ended
Stockholders’ Equity (Details 1)	Sep. 30, 2017 shares
Common Stock [Member]
Series C Warrants exercised to purchase common stock for cash at $0.001 per share	2,245,875
Net Number Cashless Exercise of Series B Warrants	7,719,958
Series A Warrent [Member]
Balance	0
Issuance of warrants	3,742,500
Series C Warrants exercised to purchase common stock for cash at $0.001 per share	0
Net Number Cashless Exercise of Series B Warrants	0
Balance	3,742,500
Series B Warrent [Member]
Balance	0
Issuance of warrants	2,495,000
Series C Warrants exercised to purchase common stock for cash at $0.001 per share	0
Net Number Cashless Exercise of Series B Warrants	(2,397,834)
Balance	97,166
Series C Warrent [Member]
Balance	0
Issuance of warrants	2,245,875
Series C Warrants exercised to purchase common stock for cash at $0.001 per share	(2,245,875)
Net Number Cashless Exercise of Series B Warrants	0
Balance	0

XML 42 R31.htm IDEA: XBRL DOCUMENT

Stockholder's Equity (Additional information) (Details) - USD ($) $ / shares in Units, $ in Millions			1 Months Ended	9 Months Ended
	Nov. 13, 2017	Aug. 09, 2016	May 23, 2017	Sep. 30, 2017	Sep. 30, 2016
Class of Warrant or Right,Exercisable Basis			The Series A warrants are exercisable, subject to certain limitations, upon issuance and expire five years from issuance and the Series B and Series C warrants are exercisable, subject to certain limitations, upon issuance and expire two years from issuance. The Series A and Series B warrants contain anti-dilution provisions that reduce the exercise price of the warrants if certain dilutive issuances occur, subject to a floor of $0.17 per share. Each of the warrants contain a cashless exercise provision in the event there is no effective registration statement covering the shares to be issued upon exercise of the warrants and a net cash settlement feature at the option of the warrant holder in certain limited circumstances in which the Company fails to timely deliver registered common shares upon a warrant exercise. Additionally, beginning 30 days after the issuance date, a Series B warrant holder is permitted to effect a cashless exercise and receive a net number of shares equal to the product of (i) 200% of the applicable warrant exercise percentage of the initial warrant amount and (ii) the quotient obtained by dividing (a) the difference obtained by subtracting (x) the market price, from (y) the initial exercise price of the Series B Warrants by (b) the market price (the Net Number Cashless Exercise).
Shares Issued, Price Per Share				$ 0.60
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 0.01
Proceeds from Issuance of Common Stock and Warrants			$ 2.5
May Public Offering [Member]
Class of Warrant or Right,Description of Exercise Price			Each share of common stock and each pre-funded Series C Warrant to purchase a share of common stock were sold together with a Series A Warrant to purchase 0.75 share of common stock and a Series B Warrant to purchase 0.50 share of common stock.
Series A Warrent [Member] \| May Public Offering [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			3,742,500
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 0.84
Common Stock [Member]
Stock And Pre-funded Series Warrants Issued During Period, Shares			2,744,125	2,744,125
Common Stock [Member] \| May Public Offering [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			2,245,875
Ladenburg Thalmann Co Inc [Member]
Proceeds from Issuance Initial Public Offering		$ 10.0
Commission Revenue percentage		3.00%
Series B Warrant [Member] \| May Public Offering [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			2,495,000
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 0.92
Series B Warrant [Member] \| Subsequent Event [Member]
Stock Issued During Period Shares Warrants Exercised Cashless	13,833
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	59,771
Series C Warrent [Member]
Shares Issued, Price Per Share				$ 0.001
Series C Warrent [Member] \| May Public Offering [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 0.60
Class of Warrant or Right,Description of Exercise Price			$0.60 of which was pre-funded at closing and $0.001 was payable upon exercise

XML 43 R32.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Details) - USD ($) $ in Thousands	Sep. 30, 2017	May 23, 2017	Dec. 31, 2016
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability		$ (2,419)
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability	$ (1,716)		$ (2,419)
Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	1,813		8,688
Restricted cash	1,835
Warrant liability	(1,716)
Fair Value, Measurements, Recurring [Member] \| Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	1,813		8,688
Restricted cash	1,835
Warrant liability	0
Fair Value, Measurements, Recurring [Member] \| Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	0		0
Restricted cash	0
Warrant liability	(1,716)
Fair Value, Measurements, Recurring [Member] \| Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	0		$ 0
Restricted cash	0
Warrant liability	$ 0

XML 44 R33.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Details 1) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Share settlement due to warrant exercises			$ (568)	$ 0
Change in fair value	$ (295)	$ 0	(135)	$ 0
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability at date of issue			(2,419)
Share settlement due to warrant exercises			568
Change in fair value			135
Warrant liability at September 30, 2017	(1,716)		(1,716)
Fair Value, Inputs, Level 2 [Member] \| Series A Warrant [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability at date of issue			(1,831)
Share settlement due to warrant exercises			0
Change in fair value			134
Warrant liability at September 30, 2017	(1,697)		(1,697)
Fair Value, Inputs, Level 2 [Member] \| Series B Warrant [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability at date of issue			(588)
Share settlement due to warrant exercises			568
Change in fair value			1
Warrant liability at September 30, 2017	$ (19)		$ (19)

XML 45 R34.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Details 2)	1 Months Ended	9 Months Ended
Fair Value Measurements (Details 2)	May 23, 2017	Sep. 30, 2017
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Risk-free interest rate	1.46%	1.99%
Contractual term	3 years 3 months 18 days	4 years 7 months 6 days
Expected volatility	85.80%	117.30%

XML 46 R35.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Additional Information) (Details) $ in Thousands	May 23, 2017 USD ($)
Derivative Liability	$ 2,419

EXCEL 47 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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
&PO=V]R:W-H965T'X_=W[0Y^\3.:% M=FS-JU_E5AP6?NY[6[:CITH\\%5U_]ZFU,G M>*V]R%!J^C8\RZ9_7K3_=S/< +0!7 U(_%^#2!M$MQK$VB"^-:1$&R2W,J3: M(#4,@J%8??7OJ:#+>7!6 MCC1F-6!@@DFFF#6""0T_]QC&\/,9P4P1#S8B_>,P8T8^CMXTDVJ1$I MALEPD@@EB2P'A! CU0%3])BFQX2S%">)49(8(8F,:L4(24APE@1E2>Q:A(51 MKP%#R(@&9HY525&6U&89Y3)QD*$.,L2!V8 8QA%ECI+D2%_DN(,"=5 @$9C% M'##)J)91%D,2AC@1"7%AAQ]WQ[T&3=MCI/\ID>,+0BRBW-%@!%
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end XML 48 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 49 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 51 FilingSummary.xml IDEA: XBRL DOCUMENT 3.8.0.1 html 96 145 1 false 32 0 false 4 false false R1.htm 101 - Document - Document And Entity Information Sheet http://www.zonagen.com/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 102 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://www.zonagen.com/role/CondensedConsolidatedBalanceSheets CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 103 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.zonagen.com/role/CondensedConsolidatedBalanceSheetsParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 104 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://www.zonagen.com/role/CondensedConsolidatedStatementsOfOperations CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 105 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? EQUITY Sheet http://www.zonagen.com/role/CondensedConsolidatedStatementsOfStockholdersEquity CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? EQUITY Statements 5 false false R6.htm 106 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? EQUITY (Parenthetical) Sheet http://www.zonagen.com/role/CondensedConsolidatedStatementsOfStockholdersEquityParenthetical CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? EQUITY (Parenthetical) Statements 6 false false R7.htm 107 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.zonagen.com/role/CondensedConsolidatedStatementsOfCashFlows CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 7 false false R8.htm 108 - Disclosure - Organization, Operations, Liquidity and Recent Developments Sheet http://www.zonagen.com/role/OrganizationOperationsLiquidityAndRecentDevelopments Organization, Operations, Liquidity and Recent Developments Notes 8 false false R9.htm 109 - Disclosure - Cash, Cash Equivalents and Restricted Cash Sheet http://www.zonagen.com/role/CashCashEquivalentsAndRestrictedCash Cash, Cash Equivalents and Restricted Cash Notes 9 false false R10.htm 110 - Disclosure - Accrued Expenses Sheet http://www.zonagen.com/role/AccruedExpenses Accrued Expenses Notes 10 false false R11.htm 111 - Disclosure - Loss Per Share Sheet http://www.zonagen.com/role/LossPerShare Loss Per Share Notes 11 false false R12.htm 112 - Disclosure - Stock-Based Compensation Sheet http://www.zonagen.com/role/StockbasedCompensation Stock-Based Compensation Notes 12 false false R13.htm 113 - Disclosure - Stockholders??? Equity Sheet http://www.zonagen.com/role/StockholdersEquity Stockholders??? Equity Notes 13 false false R14.htm 114 - Disclosure - Fair Value Measurements Sheet http://www.zonagen.com/role/FairValueMeasurements Fair Value Measurements Notes 14 false false R15.htm 115 - Disclosure - Commitments and Contingencies Sheet http://www.zonagen.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 15 false false R16.htm 116 - Disclosure - Organization, Operations, Liquidity and Recent Developments (Policies) Sheet http://www.zonagen.com/role/OrganizationOperationsLiquidityAndRecentDevelopmentsPolicies Organization, Operations, Liquidity and Recent Developments (Policies) Policies 16 false false R17.htm 117 - Disclosure - Cash, Cash Equivalents and Restricted Cash (Tables) Sheet http://www.zonagen.com/role/CashCashEquivalentsAndRestrictedCashTables Cash, Cash Equivalents and Restricted Cash (Tables) Tables http://www.zonagen.com/role/CashCashEquivalentsAndRestrictedCash 17 false false R18.htm 118 - Disclosure - Accrued Expenses (Tables) Sheet http://www.zonagen.com/role/AccruedExpensesTables Accrued Expenses (Tables) Tables http://www.zonagen.com/role/AccruedExpenses 18 false false R19.htm 119 - Disclosure - Loss Per Share (Tables) Sheet http://www.zonagen.com/role/LossPerShareTables Loss Per Share (Tables) Tables http://www.zonagen.com/role/LossPerShare 19 false false R20.htm 120 - Disclosure - Stockholders??? Equity (Tables) Sheet http://www.zonagen.com/role/StockholdersEquityTables Stockholders??? Equity (Tables) Tables http://www.zonagen.com/role/StockholdersEquity 20 false false R21.htm 121 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.zonagen.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.zonagen.com/role/FairValueMeasurements 21 false false R22.htm 122 - Disclosure - Organization, Operations, Liquidity and Recent Developments (Additional Information) (Details) Sheet http://www.zonagen.com/role/OrganizationOperationsLiquidityAndRecentDevelopmentsAdditionalInformationDetails Organization, Operations, Liquidity and Recent Developments (Additional Information) (Details) Details http://www.zonagen.com/role/OrganizationOperationsLiquidityAndRecentDevelopmentsPolicies 22 false false R23.htm 123 - Disclosure - Cash, Cash Equivalents and Restricted Cash (Details) Sheet http://www.zonagen.com/role/CashCashEquivalentsAndRestrictedCashDetails Cash, Cash Equivalents and Restricted Cash (Details) Details http://www.zonagen.com/role/CashCashEquivalentsAndRestrictedCashTables 23 false false R24.htm 124 - Disclosure - Cash, Cash Equivalents and Restricted Cash (Additional Information) (Details) Sheet http://www.zonagen.com/role/CashCashEquivalentsAndRestrictedCashAdditionalInformationDetails Cash, Cash Equivalents and Restricted Cash (Additional Information) (Details) Details http://www.zonagen.com/role/CashCashEquivalentsAndRestrictedCashTables 24 false false R25.htm 125 - Disclosure - Accrued Expenses (Details) Sheet http://www.zonagen.com/role/AccruedExpensesDetails Accrued Expenses (Details) Details http://www.zonagen.com/role/AccruedExpensesTables 25 false false R26.htm 126 - Disclosure - Loss Per Share (Calculation of Loss Per Share) (Details) Sheet http://www.zonagen.com/role/LossPerShareCalculationOfLossPerShareDetails Loss Per Share (Calculation of Loss Per Share) (Details) Details http://www.zonagen.com/role/LossPerShareTables 26 false false R27.htm 127 - Disclosure - Loss Per Share (Additional Information) (Details) Sheet http://www.zonagen.com/role/LossPerShareAdditionalInformationDetails Loss Per Share (Additional Information) (Details) Details http://www.zonagen.com/role/LossPerShareTables 27 false false R28.htm 128 - Disclosure - Stock-Based Compensation (Additional Information) (Details) Sheet http://www.zonagen.com/role/StockbasedCompensationAdditionalInformationDetails Stock-Based Compensation (Additional Information) (Details) Details http://www.zonagen.com/role/StockbasedCompensation 28 false false R29.htm 129 - Disclosure - Stockholders??? Equity (Details) Sheet http://www.zonagen.com/role/StockholdersEquityDetails Stockholders??? Equity (Details) Details http://www.zonagen.com/role/StockholdersEquityTables 29 false false R30.htm 130 - Disclosure - Stockholders??? Equity (Details 1) Sheet http://www.zonagen.com/role/StockholdersEquityDetails1 Stockholders??? Equity (Details 1) Details http://www.zonagen.com/role/StockholdersEquityTables 30 false false R31.htm 131 - Disclosure - Stockholder's Equity (Additional information) (Details) Sheet http://www.zonagen.com/role/StockholdersEquityAdditionalInformationDetails Stockholder's Equity (Additional information) (Details) Details 31 false false R32.htm 132 - Disclosure - Fair Value Measurements (Details) Sheet http://www.zonagen.com/role/FairValueMeasurementsDetails Fair Value Measurements (Details) Details http://www.zonagen.com/role/FairValueMeasurementsTables 32 false false R33.htm 133 - Disclosure - Fair Value Measurements (Details 1) Sheet http://www.zonagen.com/role/FairValueMeasurementsDetails1 Fair Value Measurements (Details 1) Details http://www.zonagen.com/role/FairValueMeasurementsTables 33 false false R34.htm 134 - Disclosure - Fair Value Measurements (Details 2) Sheet http://www.zonagen.com/role/FairValueMeasurementsDetails2 Fair Value Measurements (Details 2) Details http://www.zonagen.com/role/FairValueMeasurementsTables 34 false false R35.htm 135 - Disclosure - Fair Value Measurements (Additional Information) (Details) Sheet http://www.zonagen.com/role/FairValueMeasurementsAdditionalInformationDetails Fair Value Measurements (Additional Information) (Details) Details http://www.zonagen.com/role/FairValueMeasurementsTables 35 false false All Reports Book All Reports rprx-20170930.xml rprx-20170930.xsd rprx-20170930_cal.xml rprx-20170930_def.xml rprx-20170930_lab.xml rprx-20170930_pre.xml http://xbrl.sec.gov/dei/2014-01-31 http://fasb.org/us-gaap/2017-01-31 true true ZIP 53 0001144204-17-057993-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001144204-17-057993-xbrl.zip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